<?xml version="1.0" encoding="UTF-8" standalone="yes"?><drugRecordOutput id="62418"><DrugName>duvelisib</DrugName><DrugNamesKey><Name id="43133727">Copiktra</Name><Name id="43016215">duvelisib</Name></DrugNamesKey><DrugSynonyms><Name><Value>PI3Kdelta/gamma inhibitors (oral, inflammation/respiratory disease/cancer), Intellikine</Value></Name><Name><Value>phosphoinositide-3 kinase delta/gamma (oral, inflammation/respiratory disease/cancer), Intellikine</Value></Name><Name><Value>INK-055</Value></Name><Name><Value>INK-713</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>INK-1048</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>PI3Kdelta/gamma inhibitors (oral, inflammation/respiratory disease/cancer), Intellikine/ Infinity</Value></Name><Name><Value>IPI-145</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>PI3Kdelta/gamma inhibitors (oral, inflammation/cancer), Intellikine/ Infinity/ Mundipharma</Value></Name><Name><Value>INK-1197</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>duvelisib</Value><Types><Type>USAN</Type><Type>INN</Type></Types></Name><Name><Value>ABBV-954</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>PI3Kdelta/gamma inhibitors (cancer), Verastem/Yakult</Value></Name><Name><Value>PI3Kdelta/gamma inhibitors (cancer), Yakult</Value></Name><Name><Value>PI3K delta/gamma inhibitors (oral, cancer), Infinity/AbbVie</Value></Name><Name><Value>Copiktra</Value><Types><Type>Trade Name</Type></Types></Name><Name><Value>duvelisib hydrate (oral, inflammation/respiratory disease/cancer), Intellikine/ Infinity/Verastem/Yakult/AbbVie</Value></Name><Name><Value>duvelisib hydrate</Value></Name><Name><Value>1201438-56-3</Value><Types><Type>CAS RN</Type></Types></Name></DrugSynonyms><CompanyOriginator id="1045250">Intellikine Inc</CompanyOriginator><CompaniesPrimary><Company id="1033194">CSPC Pharmaceuticals Group Limited</Company><Company id="20961">Yakult Honsha Co Ltd</Company><Company id="1058061">Verastem Oncology</Company></CompaniesPrimary><CompaniesSecondary><Company id="1045250">Intellikine Inc</Company><Company id="1045514">Mundipharma International Corp Ltd</Company><Company id="1072507">AbbVie Inc</Company><Company id="29753">Infinity Pharmaceuticals Inc</Company></CompaniesSecondary><CrossReferences><SourceEntity id="62418" type="Drug"><TargetEntity id="676183" type="siDrug">INK-055</TargetEntity></SourceEntity><SourceEntity id="1033194" type="Company"><TargetEntity id="4296499621" type="organizationId">CSPC Holdings Co Ltd</TargetEntity></SourceEntity><SourceEntity id="1045250" type="Company"><TargetEntity id="4297944782" type="organizationId">Intellikine LLC</TargetEntity></SourceEntity><SourceEntity id="1045514" type="Company"><TargetEntity id="5035938515" type="organizationId">Mundipharma International Corp Ltd</TargetEntity></SourceEntity><SourceEntity id="1058061" type="Company"><TargetEntity id="5001437827" type="organizationId">Verastem Inc</TargetEntity></SourceEntity><SourceEntity id="1072507" type="Company"><TargetEntity id="5037613143" type="organizationId">AbbVie Inc</TargetEntity></SourceEntity><SourceEntity id="20961" type="Company"><TargetEntity id="4295878046" type="organizationId">Yakult Honsha Co Ltd</TargetEntity></SourceEntity><SourceEntity id="29753" type="Company"><TargetEntity id="4295915855" type="organizationId">Infinity Pharmaceuticals Inc</TargetEntity></SourceEntity><SourceEntity id="1734" type="ciIndication"><TargetEntity id="10008958" type="MEDDRA"/><TargetEntity id="690" type="siCondition"/></SourceEntity><SourceEntity id="1745" type="ciIndication"><TargetEntity id="C82" type="ICD10"/><TargetEntity id="D008224" type="MeSH"/><TargetEntity id="-1402578461" type="omicsDisease"/><TargetEntity id="1742" type="siCondition"/></SourceEntity><SourceEntity id="1753" type="ciIndication"><TargetEntity id="C84.4" type="ICD10"/><TargetEntity id="10034623" type="MEDDRA"/><TargetEntity id="D016411" type="MeSH"/><TargetEntity id="-585182853" type="omicsDisease"/><TargetEntity id="3114" type="siCondition"/></SourceEntity><SourceEntity id="1754" type="ciIndication"><TargetEntity id="D016410" type="MeSH"/><TargetEntity id="836" type="siCondition"/></SourceEntity><SourceEntity id="188" type="ciIndication"><TargetEntity id="10061218" type="MEDDRA"/><TargetEntity id="D007249" type="MeSH"/><TargetEntity id="-308860612" type="omicsDisease"/><TargetEntity id="1181" type="siCondition"/></SourceEntity><SourceEntity id="203" type="ciIndication"><TargetEntity id="10025310" type="MEDDRA"/><TargetEntity id="D008223" type="MeSH"/><TargetEntity id="-386134440" type="omicsDisease"/><TargetEntity id="698" type="siCondition"/></SourceEntity><SourceEntity id="2054" type="ciIndication"><TargetEntity id="10066476" type="MEDDRA"/><TargetEntity id="D019337" type="MeSH"/><TargetEntity id="-105358819" type="omicsDisease"/><TargetEntity id="1328" type="siCondition"/></SourceEntity><SourceEntity id="291" type="ciIndication"><TargetEntity id="10039073" type="MEDDRA"/><TargetEntity id="D001172" type="MeSH"/><TargetEntity id="-1391695545" type="omicsDisease"/><TargetEntity id="749" type="siCondition"/></SourceEntity><SourceEntity id="31" type="ciIndication"><TargetEntity id="J45" type="ICD10"/><TargetEntity id="493" type="ICD9"/><TargetEntity id="10003553" type="MEDDRA"/><TargetEntity id="D001249" type="MeSH"/><TargetEntity id="-1473716268" type="omicsDisease"/><TargetEntity id="270" type="siCondition"/></SourceEntity><SourceEntity id="311" type="ciIndication"><TargetEntity id="10042971" type="MEDDRA"/><TargetEntity id="D016399" type="MeSH"/><TargetEntity id="-664594417" type="omicsDisease"/><TargetEntity id="704" type="siCondition"/></SourceEntity><SourceEntity id="319" type="ciIndication"><TargetEntity id="10029547" type="MEDDRA"/><TargetEntity id="D008228" type="MeSH"/><TargetEntity id="547" type="ORPHANET"/><TargetEntity id="-1008757452" type="omicsDisease"/><TargetEntity id="703" type="siCondition"/></SourceEntity><SourceEntity id="36" type="ciIndication"><TargetEntity id="10061664" type="MEDDRA"/><TargetEntity id="D001327" type="MeSH"/><TargetEntity id="-2072222280" type="omicsDisease"/><TargetEntity id="729" type="siCondition"/></SourceEntity><SourceEntity id="651" type="ciIndication"><TargetEntity id="576" type="siCondition"/></SourceEntity><SourceEntity id="711" type="ciIndication"><TargetEntity id="J98.9" type="ICD10"/><TargetEntity id="10038683" type="MEDDRA"/><TargetEntity id="D012140" type="MeSH"/><TargetEntity id="-2143937119" type="omicsDisease"/><TargetEntity id="269" type="siCondition"/></SourceEntity><SourceEntity id="11183" type="Action"><TargetEntity id="2483" type="Mechanism">Phosphatidylinositol 3-Kinase delta (PI3Kdelta) Inhibitors</TargetEntity></SourceEntity><SourceEntity id="11186" type="Action"><TargetEntity id="2489" type="Mechanism">Phosphatidylinositol 3-Kinase gamma (PI3Kgamma) Inhibitors</TargetEntity></SourceEntity><SourceEntity id="1589" type="Action"><TargetEntity id="1062" type="Mechanism">Apoptosis Inducers</TargetEntity></SourceEntity><SourceEntity id="PTGT-02712" type="ciTarget"><TargetEntity id="49772453852933" type="siTarget">Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform</TargetEntity><TargetEntity id="-1581688045" type="omicsTarget"/></SourceEntity><SourceEntity id="PTGT-02713" type="ciTarget"><TargetEntity id="51802555152943" type="siTarget">Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform</TargetEntity><TargetEntity id="-848857411" type="omicsTarget"/></SourceEntity></CrossReferences><PhaseHighest id="L">Launched</PhaseHighest><PhaseHighestDetailed><FirstLaunched>Chronic lymphocytic leukemia - US - Sep-2018</FirstLaunched><FirstLaunched>Follicle center lymphoma - US - Sep-2018</FirstLaunched></PhaseHighestDetailed><RegulatoryDesignations><RegulatoryDesignation id="5">Accelerated Approval</RegulatoryDesignation><RegulatoryDesignation id="2">Fast Track</RegulatoryDesignation><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><RegulatoryDesignation id="11">Priority Review</RegulatoryDesignation></RegulatoryDesignations><IndicationsPrimary><Indication id="1734">Chronic lymphocytic leukemia</Indication><Indication id="1745">Follicle center lymphoma</Indication><Indication id="1753">Peripheral T-cell lymphoma</Indication><Indication id="203">Lymphoma</Indication><Indication id="2054">Hematological neoplasm</Indication><Indication id="311">T-cell lymphoma</Indication><Indication id="319">Non-Hodgkin lymphoma</Indication><Indication id="651">Cancer</Indication></IndicationsPrimary><IndicationsSecondary><Indication id="1754">Cutaneous T-cell lymphoma</Indication><Indication id="188">Inflammatory disease</Indication><Indication id="291">Rheumatoid arthritis</Indication><Indication id="31">Asthma</Indication><Indication id="36">Autoimmune disease</Indication><Indication id="711">Respiratory disease</Indication></IndicationsSecondary><ActionsPrimary><Action id="11186">Phosphoinositide-3 kinase gamma inhibitor</Action><Action id="11183">Phosphoinositide-3 kinase delta inhibitor</Action></ActionsPrimary><ActionsSecondary><Action id="1589">Apoptosis stimulator</Action><Action id="396">Immunosuppressant</Action><Action id="62255">Anticancer protein kinase inhibitor</Action></ActionsSecondary><Technologies><Technology id="586">Capsule formulation</Technology><Technology id="762">Small molecule therapeutic</Technology><Technology id="585">Oral formulation</Technology></Technologies><EphmraCodes><Ephmra><Code>L4</Code><Name>IMMUNOSUPPRESSIVE AGENTS</Name></Ephmra></EphmraCodes><LastModificationDate>2019-06-27T06:17:42.000Z</LastModificationDate><ChangeDateLast>2019-06-27T00:00:00.000Z</ChangeDateLast><AddedDate>2009-01-30T15:46:41.000Z</AddedDate><DevelopmentProfile><Summary><displayLabel>Summary</displayLabel><value>&lt;Summary&gt;&lt;para&gt;&lt;ulink linkID="1058061" linkType="Company"&gt;Verastem&lt;/ulink&gt;, under  license from &lt;ulink linkID="29753" linkType="Company"&gt;Infinity Pharmaceuticals&lt;/ulink&gt;, which originally licensed the drug from  &lt;ulink linkID="1045250" linkType="Company"&gt;Intellikine&lt;/ulink&gt; (a subsidiary of &lt;ulink linkID="20300" linkType="Company"&gt;Takeda&lt;/ulink&gt;), and licensees &lt;ulink linkID="20961" linkType="Company"&gt;Yakult Honsha&lt;/ulink&gt;  and &lt;ulink linkID="1033194" linkType="Company"&gt;CSPC Pharmaceuticals&lt;/ulink&gt; have  developed and launched a capsule formulation of duvelisib hydrate (Copiktra; IPI-145, INK-1197, ABBV-954; structure shown), the lead from a program of orally  available dual inhibitor of  phosphoinositide-3 kinase delta/gamma (PI3Kdelta/gamma),  also including INK-055 [&lt;ulink linkID="2015652" linkType="Reference"&gt;2015652&lt;/ulink&gt;], [&lt;ulink linkID="2132325" linkType="Reference"&gt;2132325&lt;/ulink&gt;]. In the US, the drug is indicated for the treatment of  relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) after at least two prior  therapies, and for the treatment of relapsed or refractory follicular lymphoma (FL) after at least two prior systemic therapies [&lt;ulink linkID="2076126" linkType="Reference"&gt;2076126&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In September 2018, the FDA approved the drug for the  treatment of  relapsed or refractory CLL or SLL after at least two prior  therapies; at that time, the drug was also approved under accelerated approval for the treatment of relapsed or refractory FL after at least two prior systemic therapies; launch occurred immediately [&lt;ulink linkID="2075937" linkType="Reference"&gt;2075937&lt;/ulink&gt;],  [&lt;ulink linkID="2076482" linkType="Reference"&gt;2076482&lt;/ulink&gt;], [&lt;ulink linkID="2077044" linkType="Reference"&gt;2077044&lt;/ulink&gt;]. In April 2018, an EU  regulatory filing was planned for the end of 2018   [&lt;ulink linkID="2020301" linkType="Reference"&gt;2020301&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;The product is also being evaluated in other cancer settings, including indolent non-Hodgkin lymphoma (iNHL) and T-cell lymphoma. In May 2013, Infinity started a phase II trial in iNHL [&lt;ulink linkID="1518351" linkType="Reference"&gt;1518351&lt;/ulink&gt;]; in June 2016, positive topline results were reported [&lt;ulink linkID="1772437" linkType="Reference"&gt;1772437&lt;/ulink&gt;]; in May 2018, the study was ongoing [&lt;ulink linkID="1518351" linkType="Reference"&gt;1518351&lt;/ulink&gt;]. In January 2014, Infinity initiated a phase I trial in   T-cell lymphoma [&lt;ulink linkID="1518220" linkType="Reference"&gt;1518220&lt;/ulink&gt;]; in June 2015, clinical data were presented [&lt;ulink linkID="1670527" linkType="Reference"&gt;1670527&lt;/ulink&gt;]. In November 2015, Infinity and former partner &lt;ulink linkID="1072507" linkType="Company"&gt;AbbVie&lt;/ulink&gt; had begun a phase I study  in Japanese subjects with relapsed or refractory lymphoma [&lt;ulink linkID="1726217" linkType="Reference"&gt;1726217&lt;/ulink&gt;], [&lt;ulink linkID="1747936" linkType="Reference"&gt;1747936&lt;/ulink&gt;]; in March 2016, AbbVie listed the drug as being in phase I/II development for hematological cancers in Japan [&lt;ulink linkID="1747791" linkType="Reference"&gt;1747791&lt;/ulink&gt;]. In February 2018, a phase II trial (PRIMO) in PTCL patients was initiated [&lt;ulink linkID="1994404" linkType="Reference"&gt;1994404&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;Infinity was previously investigating the product in follicular lymphoma (FL). In September 2014, a phase III trial in FL was initiated [&lt;ulink linkID="1593369" linkType="Reference"&gt;1593369&lt;/ulink&gt;]; however, in February 2016, Infinity stated that the trial had been closed because of  difficulties enrolling patients [&lt;ulink linkID="1737218" linkType="Reference"&gt;1737218&lt;/ulink&gt;], [&lt;ulink linkID="1737249" linkType="Reference"&gt;1737249&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;Infinity was previously investigating the drug for inflammatory conditions including rheumatoid arthritis (RA) and asthma. In May 2013 a phase II trial began in RA [&lt;ulink linkID="1416791" linkType="Reference"&gt;1416791&lt;/ulink&gt;]; however, in January 2015, negative topline data were reported  [&lt;ulink linkID="1625120" linkType="Reference"&gt;1625120&lt;/ulink&gt;]. In February 2015, Infinity confirmed that development of the drug for inflammatory conditions had been halted following these data [&lt;ulink linkID="1641884" linkType="Reference"&gt;1641884&lt;/ulink&gt;].&lt;/para&gt;&lt;/Summary&gt;</value></Summary><PatentsAndGenerics><displayLabel>Patents and Generics</displayLabel><value>&lt;PatentsAndGenerics&gt;&lt;para&gt;The product case which claims the compound is based on &lt;ulink linkID="PA6320521" linkType="Patent"&gt;WO-2011008302&lt;/ulink&gt;, which  is based on &lt;ulink linkID="PA5320024" linkType="Patent"&gt;WO-2009088986&lt;/ulink&gt; and &lt;ulink linkID="PA5320217" linkType="Patent"&gt;WO-2009088990&lt;/ulink&gt;. By August 2014, three US patents (&lt;ulink linkID="PA5461363" linkType="Patent"&gt;US-08193182&lt;/ulink&gt;, &lt;ulink linkID="PA7102205" linkType="Patent"&gt;US-08569323&lt;/ulink&gt;, &lt;ulink linkID="PA6888031" linkType="Patent"&gt;US-08785456&lt;/ulink&gt;) had been granted in this family, which expire between January 2029 and February 2030. By February 2016, Infinity had eight issued or allowed US patents, which expire on between 2029 and 2032 [&lt;ulink linkID="1737218" linkType="Reference"&gt;1737218&lt;/ulink&gt;]. By March 2017, also &lt;ulink linkID="PA7972197" linkType="Patent"&gt;US-09216982&lt;/ulink&gt; had been granted, which was due to expire in January 2029. At that time, related issued and pending worldwide patents and applications with claims to duvelisib, pharmaceutical compounds, methods of use, polymorphs, and methods of manufacture were pending in about 40 countries with additional applications related to certain methods of use and combination therapies, if granted, expected to expire between 2029 and 2036 [&lt;ulink linkID="1911968" linkType="Reference"&gt;1911968&lt;/ulink&gt;]; in March 2018, this was still the case [&lt;ulink linkID="2015652" linkType="Reference"&gt;2015652&lt;/ulink&gt;].&lt;/para&gt;&lt;/PatentsAndGenerics&gt;</value></PatentsAndGenerics><Regulatory><displayLabel>Regulatory</displayLabel><value>&lt;Regulatory&gt;&lt;para&gt;&lt;subtitle&gt;The US&lt;/subtitle&gt;&lt;subtitle&gt;Chronic lymphocytic leukemia&lt;/subtitle&gt;In June 2016, following the termination of the collaboration with AbbVie, Infinity was continuing to focus on a US filing     [&lt;ulink linkID="1776420" linkType="Reference"&gt;1776420&lt;/ulink&gt;]. In January 2017, Verastem planned to launch the drug after the report of phase III DUO data [&lt;ulink linkID="1893998" linkType="Reference"&gt;1893998&lt;/ulink&gt;]. In February 2018, Verastem submitted an NDA to the FDA for relapsed or refractory CLL/SLL, based on the results from the DUO and DYNAMO studies [&lt;ulink linkID="2003428" linkType="Reference"&gt;2003428&lt;/ulink&gt;]. In April 2018, the FDA accepted the NDA for  Priority Review   with a PDUFA date of October 5, 2018. The company planned to launch the product immediately if approved   [&lt;ulink linkID="2020301" linkType="Reference"&gt;2020301&lt;/ulink&gt;]. In September 2018, the FDA approved the drug for the  treatment of  relapsed or refractory CLL or SLL after at least two prior  therapies; launch occurred immediately [&lt;ulink linkID="2075937" linkType="Reference"&gt;2075937&lt;/ulink&gt;], [&lt;ulink linkID="2076482" linkType="Reference"&gt;2076482&lt;/ulink&gt;], [&lt;ulink linkID="2077044" linkType="Reference"&gt;2077044&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In April 2013, the FDA granted the drug Orphan status for the treatment of CLL and SLL [&lt;ulink linkID="1408141" linkType="Reference"&gt;1408141&lt;/ulink&gt;]. In August 2015, the FDA granted Fast Track designation for duvelisib for the treatment of patients with CLL who have received at least one prior therapy [&lt;ulink linkID="1684309" linkType="Reference"&gt;1684309&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Non-Hodgkin lymphoma&lt;/subtitle&gt;In June 2016, following the termination of the collaboration with AbbVie, Infinity was continuing to focus on a US filing. The company planned to discuss in a meeting with  the FDA the potential for FRESCO to be a confirmatory study for full approval in follicular lymphoma if duvelisib received an Accelerated Approval based on the DYNAMO study [&lt;ulink linkID="1776420" linkType="Reference"&gt;1776420&lt;/ulink&gt;]. In February 2018, Versastem submitted an NDA to the FDA requesting Accelerated Approval for relapsed or refractory follicular lymphoma, based on the results from the DUO and DYNAMO studies [&lt;ulink linkID="2003428" linkType="Reference"&gt;2003428&lt;/ulink&gt;].  In April 2018, the FDA accepted the NDA for  Priority Review   with a PDUFA date of October 05, 2018. The company planned to launch the product immediately if approved [&lt;ulink linkID="2020301" linkType="Reference"&gt;2020301&lt;/ulink&gt;]. In September 2018, the FDA approved the drug under accelerated approval for the treatment of relapsed or refractory FL after at least two prior systemic therapies based on overall response rate (ORR); launch occurred immediately [&lt;ulink linkID="2075937" linkType="Reference"&gt;2075937&lt;/ulink&gt;], [&lt;ulink linkID="2076482" linkType="Reference"&gt;2076482&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;In August 2013, Orphan designation was granted for follicular lymphoma [&lt;ulink linkID="1462442" linkType="Reference"&gt;1462442&lt;/ulink&gt;]. By March 2017, the FDA had granted Fast Track designation for patients with follicular lymphoma who have received at least two prior therapies [&lt;ulink linkID="1911968" linkType="Reference"&gt;1911968&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Peripheral T-cell lymphoma&lt;/subtitle&gt;In September 2017, the drug was granted US Fast Track status for patients with PTCL who have received at least one prior therapy [&lt;ulink linkID="1959382" linkType="Reference"&gt;1959382&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Europe&lt;/subtitle&gt;&lt;subtitle&gt;Chronic lymphocytic leukemia&lt;/subtitle&gt;In April 2018, a regulatory filing for the EU was planned for the end of 2018   [&lt;ulink linkID="2020301" linkType="Reference"&gt;2020301&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In March 2013, the EMA's COMP recommended Orphan status for the treatment of CLL and SLL [&lt;ulink linkID="1394087" linkType="Reference"&gt;1394087&lt;/ulink&gt;]; in April 2013, Orphan designation was granted [&lt;ulink linkID="1429040" linkType="Reference"&gt;1429040&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Non-Hodgkin lymphoma&lt;/subtitle&gt;In  April 2018, a regulatory filing for the EU was planned for the end of 2018   [&lt;ulink linkID="2020301" linkType="Reference"&gt;2020301&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In June 2013, the COMP recommended Orphan designation for follicular lymphoma [&lt;ulink linkID="1442730" linkType="Reference"&gt;1442730&lt;/ulink&gt;]; in July 2013, Orphan status was granted [&lt;ulink linkID="1475233" linkType="Reference"&gt;1475233&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;SAFETY INFORMATION&lt;/subtitle&gt;The US label carries  a black box warning highlighting the risk of fatal and serious infections, diarrhea or colitis, cutaneous reactions and pneumonitis [&lt;ulink linkID="2076126" linkType="Reference"&gt;2076126&lt;/ulink&gt;]. &lt;/para&gt;&lt;/Regulatory&gt;</value></Regulatory><Premarketing><displayLabel>Premarketing</displayLabel><value>&lt;Premarketing&gt;&lt;para&gt;&lt;subtitle&gt;Chronic lymphocytic leukemia/small cell lymphocytic leukemia&lt;/subtitle&gt;&lt;subtitle&gt;Phase III&lt;/subtitle&gt;In March 2019, pooled efficacy and safety data from four clinical studies in patients with relapsed or refractory CLL/SLL who received duvelisib monotherapy for more than 2 years were presented at the Annual International Congress on Hematologic Malignancies in Miami, FL.  In the 46 patients,  89% ORR, 20% CR and 70% PR were reported; median PFS was 40 months. In patients (n = 10) with 17p deletion/TP53 mutation, a 100% ORR, 30% CR and 70% PR was acheived, with a median PFS of 38 months. No new safety signals were reported and the AEs reported were similar to those in patients who were administered the drug for less than 2 years [&lt;ulink linkID="2127249" linkType="Reference"&gt;2127249&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In July 2018, an investigator led, single-group assignment, open-label, phase I/II clinical trial (&lt;ulink linkID="340395" linkType="Protocol"&gt;NCT03534323&lt;/ulink&gt;; 18-089) investigating duvelisib and &lt;ulink linkID="70895" linkType="Drug"&gt;venetoclax&lt;/ulink&gt; in patients (expected n = 47) with relapsed or refractory CLL or SLL was initiated in the US. The primary endpoint was the maximum tolerated dose of venetoxlax when administered with dubelisib. The phase II primary endpoint was to determine the rate of CR of the combination. At that time, the study was due to complete in June 2024 [&lt;ulink linkID="2070795" linkType="Reference"&gt;2070795&lt;/ulink&gt;].  In September 2018, the first patient was dosed [&lt;ulink linkID="2070793" linkType="Reference"&gt;2070793&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;In January 2015, an open label, non-randomized, parallel assignment, phase III trial (&lt;ulink linkID="170720" linkType="Protocol"&gt;NCT02049515&lt;/ulink&gt;; IPI-145-12) was initiated in patients (expected n = 152), in the US, Australia, Europe and New Zealand to evaluate the efficacy of duvelisib monotherapy or &lt;ulink linkID="42299" linkType="Drug"&gt;ofatumumab&lt;/ulink&gt; monotherapy in subjects with CLL who experienced disease progression after treatment with duvelisib or ofatumumab in study IPI-145-07 [&lt;ulink linkID="1634526" linkType="Reference"&gt;1634526&lt;/ulink&gt;].  In June 2018, clinical data from 89 patients who voluntarily crossed over following radiologically confirmed disease progression on ofatumumab on DUO were presented at the 54th ASCO Annual Meeting in Chicago, IL. ORR was 73%, with CR of 0%, CR with incomplete marrow recovery (CRi) of 5%, partial response of 57%, PR with lymphocytosis (PRwL) of 11%. For patients with 17p deletion treated with duvelisib, the ORR was 80%, which included two CRi, 13 PR and 1 PRwL. PFS (per Investigator Assessment) was 15 months. A greater than 50% reduction in target nodal lesions was observed in 83% of patients. Pneumocystis jirovecii pneumonia was the only adverse event on study led to death assessed as related to duvelisib [&lt;ulink linkID="2040017" linkType="Reference"&gt;2040017&lt;/ulink&gt;] [&lt;ulink linkID="2034966" linkType="Reference"&gt;2034966&lt;/ulink&gt;] [&lt;ulink linkID="2041304" linkType="Reference"&gt;2041304&lt;/ulink&gt;]. In August 2018, the trial was expected to complete in December 2018 [&lt;ulink linkID="1634526" linkType="Reference"&gt;1634526&lt;/ulink&gt;].  In December 2018, data from 90 patients with disease progression on ofatumumab and later crossed-over to duvelisib were presented at the 60th ASH Annual Meeting and Exposition in San Diego, CA. During pre-crossover and post-crossover among all patients, the ORR was 29 and 77%; CR/CRi rate was 1 and 4%; PR rate was 28 and 62%; PRwL rate was 0 and 11% and median PFS was 9.4 and 15.2 months, respectively [&lt;ulink linkID="2098675" linkType="Reference"&gt;2098675&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In November 2013, a phase III, randomized open label, parallel assignment phase III trial (&lt;ulink linkID="163157" linkType="Protocol"&gt;NCT02004522&lt;/ulink&gt;; IPI-145-07; DUO) study began to compare duvelisib with &lt;ulink linkID="42299" linkType="Drug"&gt;ofatumumab&lt;/ulink&gt; in 300 patients with relapsed or refractory CLL and SLL in the US to evaluate the overall survival, progression-free survival (PFS) and overall response rate of duvelisib versus ofatumumab [&lt;ulink linkID="1509881" linkType="Reference"&gt;1509881&lt;/ulink&gt;]. In January 2015, the trial was ongoing in Australia, Europe and New Zealand [&lt;ulink linkID="1509881" linkType="Reference"&gt;1509881&lt;/ulink&gt;]. In November 2015, 300-patient target enrollment  was complete [&lt;ulink linkID="1714023" linkType="Reference"&gt;1714023&lt;/ulink&gt;].  In September 2017, positive topline data from the 319-patient trial were reported, showing superiority of duvelisib monotherapy over ofatumumab, with median progression-free survival of 13.3 versus 9.9 months (hazard ratio of 0.52; p&amp;lt;0.0001; 48% reduction in the risk of progression or death). Median PFS in patients with 17p deletion was 12.7 versus 9.0 months (hazard ratio of 0.41; p=0.0011) [&lt;ulink linkID="1959381" linkType="Reference"&gt;1959381&lt;/ulink&gt;]. In December 2017, further data were presented at the 59th ASH Annual Meeting and Exposition in Atlanta, GA. In duvelisib and ofatumumab treatment groups, overall response rate was 73.8 and 45.3% (p &amp;lt; 0.0001); and lymph node response rate (&amp;gt;/= 50% decrease in lymph node burden) was 85.0 and 15.7%, respectively. The safety profile of duvelisib was manageable and consistent. Adverse events of special interest included rash, pneumonitis, transaminitis, colitis, pneumonia, diarrhea and neutropenia [&lt;ulink linkID="1988359" linkType="Reference"&gt;1988359&lt;/ulink&gt;], [&lt;ulink linkID="1988152" linkType="Reference"&gt;1988152&lt;/ulink&gt;], [&lt;ulink linkID="1990186" linkType="Reference"&gt;1990186&lt;/ulink&gt;].  In June 2018, further data were presented at the 54th ASCO Annual Meeting in Chicago, IL. Treatment with both duvelisib and ofatumumab resulted in significant reduction of eleven chemokines; of those, eight decreased with duvelisib greater than ofatumumab (p&amp;lt;/=0.001). At 12-month, estimated event-free rates were observed in CCL17 (40 and 55%), VEGFD (40 and 50%), CXCL10 (43 and 52%), IL-10 (45 and 50%), CCL19 (41 and 62%), IL-15 (47 and 51%), CCL-15 (39 and 57%), IL-6 (46 and 50%) and TRAIL analytes (36 and 72%), respectively. DOR (&amp;gt;16.1 months) was significantly reduced by duvelisib (&amp;gt;/=5 months than the median DOR for duvelisib) in CCL17, CXCL10, IL-10, CCL19 and CCL15, respectively; and significant reductions in DOR was also observed in VEGFD, IL-15 and 6 and TRAIL analytes and median DOR was not reached [&lt;ulink linkID="2039347" linkType="Reference"&gt;2039347&lt;/ulink&gt;].  Later that month, further data were presented at the 23rd EHA Annual Congress in Stockholm, Sweden. There was a correlation between duration of response and reduction (highest quartile [Q]) was observed for (19.4 months. quartile 4 versus 10.4 months quartile 1 to 3), CXCL11 (14.9 months, quartile 4 versus 10.9 months quartile 1 to 3) IL-6 (16.6 months quartile 4 versus 10.9 months quartile 1 to 3), TRAIL (24 months quartile 4 versus 10.3 months quartile 1 to 3), VEGF-D (24 months quartile 4 versus 10.9 months quartile 1 to 3), TPO (14.9 months quartile 4 versus 10.9 months quartile 1 to 3) CCL17 [&lt;ulink linkID="2045668" linkType="Reference"&gt;2045668&lt;/ulink&gt;], [&lt;ulink linkID="2045424" linkType="Reference"&gt;2045424&lt;/ulink&gt;]. In August 2018, the trial was expected to complete in June 2021 [&lt;ulink linkID="1509881" linkType="Reference"&gt;1509881&lt;/ulink&gt;]. In October 2018, data from the trial were published [&lt;ulink linkID="2079633" linkType="Reference"&gt;2079633&lt;/ulink&gt;], [&lt;ulink linkID="2079633" linkType="Reference"&gt;2079633&lt;/ulink&gt;],  [&lt;ulink linkID="2079373" linkType="Reference"&gt;2079373&lt;/ulink&gt;], [&lt;ulink linkID="2080165" linkType="Reference"&gt;2080165&lt;/ulink&gt;]. In December 2018, further data were presented at 60th ASH Annual Meeting and Exposition in San Diego, CA. The initial multivariate analysis demonstrated that Trisomy 12-absent (HR -/+ 0.15), CCL22 (L) (HR H/L 2.23), TNF-alpha (L) (HR H/L 3.66), Treg (H) (HR H/L 0.31) and monocytes (L) HR H/L 2.45) were associated with longer PFS, while in TNF-alpha (L) and Treg (H) largest association was observed with estimated 73 and 69%, respectively, reductions in risk of progression or death. Duvelisib monotherapy was highly efficacious in CLL patients with markers of poor response, including high tumor burden, del(17p), and del(11q) as shown by univariate analyses of tumor burden, cytogenetics, immune cell profiles and serum factors [&lt;ulink linkID="2098262" linkType="Reference"&gt;2098262&lt;/ulink&gt;]. In March 2019, similar data were presented at the Annual International Congress on Hematologic Malignancies in Miami, FL, showing patients who had previously received at least two prior therapies demonstrated a 78% ORR and PFS of 16.4 months on the drug compared with 39% and 9.1 months for ofatumumab, respectively  [&lt;ulink linkID="2125197" linkType="Reference"&gt;2125197&lt;/ulink&gt;], [&lt;ulink linkID="2127249" linkType="Reference"&gt;2127249&lt;/ulink&gt;]. By March 2019, similar data were published [&lt;ulink linkID="2128941" linkType="Reference"&gt;2128941&lt;/ulink&gt;]. In June 2019, further data were presented at the 55th ASCO Annual Meeting in Chicago, IL. Similar PFS (primary endpoint) was observed between patients with &amp;gt;/= 1 dose interruption (DI) and those without DI for &amp;gt; 1 week or &amp;gt; 2 weeks within the first 3 months of therapy (mPFS:Â  &amp;gt; 1 week, 17.8 versus 16.3 months; &amp;gt; 2 weeks, 17.8 versus 16.3 months). Within the first 3 and 6 months of therapy, PFS did not appear shorter in patients with dose reduction (DR) relative to those without DR [&lt;ulink linkID="2156466" linkType="Reference"&gt;2156466&lt;/ulink&gt;] [&lt;ulink linkID="2152162" linkType="Reference"&gt;2152162&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Phase II&lt;/subtitle&gt;In February 2018, an open label, single arm, multi-center, phase II study (&lt;ulink linkID="322422" linkType="Protocol"&gt;NCT03370185&lt;/ulink&gt;; VS-0145-224) was initiated in patients (expected) with CLL/SLL, who had been previously treated with ibrutinib or another Bruton's Tyrosine Kinase Inhibitor (BTKi) and relapsed or were refractory to such therapy or discontinued such therapy due to toxicity, to evaluate efficacy and safety of the drug. The primary endpoint of the trial was to determine the overall response rate from initiation of treatment to first documented response in 2 cycles for a timeframe of 58 days. At that time, the trial was to complete in March 2021 [&lt;ulink linkID="2040770" linkType="Reference"&gt;2040770&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Phase I/II&lt;/subtitle&gt;In July 2014, an open-label phase I/II trial (&lt;ulink linkID="194769" linkType="Protocol"&gt;NCT02158091&lt;/ulink&gt;) began to evaluate duvelisib in combination with FCR (fludarabine, cyclophosphamide and &lt;ulink linkID="6736" linkType="Drug"&gt;Rituxan&lt;/ulink&gt;)  in previously untreated non-elderly patients (&amp;lt;65 years) with CLL. The primary endpoint was rate of minimal disease complete response in the bone marrow at 2 months after the last cycle of FCR. The trial was to enroll 26 patients and complete in July 2021 [&lt;ulink linkID="1584975" linkType="Reference"&gt;1584975&lt;/ulink&gt;]. In June 2018, clinical data were presented at the 23rd EHA Annual Congress in Stockholm, Sweden. Grade 3 febrile neutropenia at 25 mg QD (n = 1) was the only DLT reported, and the MTD (RP2D) of duvelisib observed was 25 mg bid. In 29 pts evaluable for post-FCR response, the overall response rate observed was 97%, with 28% of patients achieved complete response (CR) and 69% of patients achieved partial response (PR). The best rate of minimal residual disease negativity (MRD-) in the bone marrow (BM) in patients with at least one evaluation was 81%. The rate of complete remission (CR)/CR with incomplete marrow recovery with BM-MRD- (primary efficacy endpoint) observed was 28% [&lt;ulink linkID="2045593" linkType="Reference"&gt;2045593&lt;/ulink&gt;] [&lt;ulink linkID="2045424" linkType="Reference"&gt;2045424&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Phase I&lt;/subtitle&gt;In September 2014, a phase Ib study of duvelisib in combination with &lt;ulink linkID="53227" linkType="Drug"&gt;obinutuzumab&lt;/ulink&gt; in patients with CLL whose disease had progressed following treatment with a Bruton's tyrosine kinase inhibitor was planned to start later that year  [&lt;ulink linkID="1590188" linkType="Reference"&gt;1590188&lt;/ulink&gt;]. In February 2015, the non-randomized, open-label, single-group-assignment, dose-escalation, safety and tolerability, phase Ib trial (&lt;ulink linkID="216024" linkType="Protocol"&gt;NCT02292225&lt;/ulink&gt;; IPI-145-18; SYNCHRONY) was initiated in the US and Canada in patients (expected n = 46) with CLL/SLL. The primary endpoint was the incidence of DLTs during 28 days of treatment and treatment-emergent adverse events up to 30 days after the last dose. At that time, the trial was expected to complete in November 2021[&lt;ulink linkID="1683138" linkType="Reference"&gt;1683138&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Peripheral T-cell lymphoma&lt;/subtitle&gt;In June 2019,  phase I clinical data were presented at the 2019 International Conference on Malignant Lymphoma in Lugano, Switzerland, which were supportive of the ongoing phase II PRIMO trial; data from two phase I trials showed patients who received duvelisib had an ORR of 54 and 44%, and CR rate of 15 and 22%, respectively. The ORR in patients who received duvelisib twice daily as lead-in monotherapy before bortezombin was 57%. In the dose escalation study, median PFS was 8.3 months, and median OS was 16.2 months. The safety profile was consistant with previously reported data [&lt;ulink linkID="2166893" linkType="Reference"&gt;2166893&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In September 2017, a phase II trial  (PRIMO) in relapsed or refractory PTCL was being planned in the US and Japan [&lt;ulink linkID="1959382" linkType="Reference"&gt;1959382&lt;/ulink&gt;]. In February 2018, the sequentially assigned, parallel group, multicenter, phase II trial (&lt;ulink linkID="322539" linkType="Protocol"&gt;NCT03372057&lt;/ulink&gt;; VS-0145-225)  was initiated in the US to evaluate the efficacy and safety of duvelisib in patients (expected n = 120)  with r/r PTCL. The primary endpoint was the ORR from the start of the treatment to the first documented response, assessed up to 58 days. At that time, the trial was expected to complete in December 2021 [&lt;ulink linkID="1994404" linkType="Reference"&gt;1994404&lt;/ulink&gt;]. By May 2018, recruitment had commenced in the EU and Japan in the PRIMO trial  [&lt;ulink linkID="2030492" linkType="Reference"&gt;2030492&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Follicular lymphoma&lt;/subtitle&gt;&lt;subtitle&gt;Phase III&lt;/subtitle&gt;In January 2019, a phase III confirmatory study to evaluate duvelisib for the treatment of patients with relapsed or refractory FL after at least two prior systemic therapies was planned. At that time, the trial was planned to begin in 2H19 [&lt;ulink linkID="2108160" linkType="Reference"&gt;2108160&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In September 2014, a phase III, randomized, placebo-controlled study (DYNAMO+R; &lt;ulink linkID="207044" linkType="Protocol"&gt;NCT02204982&lt;/ulink&gt;; IPI-145-08, 2013-002406-31) of duvelisib in combination with &lt;ulink linkID="6736" linkType="Drug"&gt;rituximab&lt;/ulink&gt; in patients (expected n = 450) with previously treated CD20-positive FL was initiated in the US [&lt;ulink linkID="1515189" linkType="Reference"&gt;1515189&lt;/ulink&gt;], [&lt;ulink linkID="1523400" linkType="Reference"&gt;1523400&lt;/ulink&gt;], [&lt;ulink linkID="1593369" linkType="Reference"&gt;1593369&lt;/ulink&gt;]. In December 2014, the trial was ongoing in Australia, Belgium, Hungary, Italy, New Zealand and Spain [&lt;ulink linkID="1593369" linkType="Reference"&gt;1593369&lt;/ulink&gt;]. In October 2015, Infinity stated that patient recruitment had been slower than expected [&lt;ulink linkID="1700592" linkType="Reference"&gt;1700592&lt;/ulink&gt;]. In February 2016, Infinity stated that the trial had been closed because of  difficulties enrolling patients [&lt;ulink linkID="1737218" linkType="Reference"&gt;1737218&lt;/ulink&gt;], [&lt;ulink linkID="1737249" linkType="Reference"&gt;1737249&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Phase II&lt;/subtitle&gt;In December 2015, a randomized, parallel-group, open-label, phase II study (&lt;ulink linkID="246010" linkType="Protocol"&gt;NCT02605694&lt;/ulink&gt;; IPI-145-21; 2015-004729-15; FRESCO) was initiated in the US to evaluate the safety and efficacy of duvelisib in combination with &lt;ulink linkID="6736" linkType="Drug"&gt;rituximab&lt;/ulink&gt; compared with R-CHOP for patients (expected n = 230) with relapsed/refractory follicular lymphoma. The primary endpoint would be progression-free survival. However, in July 2017, the study was withdrawn, due to Verastem focusing on other studies to enable the registration of duvelisib [&lt;ulink linkID="1738237" linkType="Reference"&gt;1738237&lt;/ulink&gt;], [&lt;ulink linkID="1737676" linkType="Reference"&gt;1737676&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In December 2014, a two-arm phase I/IIb trial (&lt;ulink linkID="224839" linkType="Protocol"&gt;NCT02391545&lt;/ulink&gt;; CONTEMPO) of duvelisib in combination with rituximab or obinutuzumab was initiated in the US and Europe in patients with previously untreated follicular lymphoma. The trial enrolled 55 patients and completed in May 2017 [&lt;ulink linkID="1957622" linkType="Reference"&gt;1957622&lt;/ulink&gt;]. In June 2016, clinical data from the ongoing study (were presented at the 52nd ASCO meeting in Chicago, IL. Tmax of approximately 1 h; Cmax of approximately 910 ng/ml was observed with single dose of duvelisib; while after multiple doses, plasma steady state levels were approximately 500 to 540 ng/ml and approximately half of the duvelisib was transformed into its metabolite IPI-656 [&lt;ulink linkID="1786202" linkType="Reference"&gt;1786202&lt;/ulink&gt;]. In June 2016, further data were presented at the 21st EHA Annual Meeting in Copenhagen, Denmark. There was only 1 DLT, in the obinutuzumab combination arm (grade 3 elevated lipase on day 8). Of 9 patients evaluable in this arm, 33% showed a complete response (CR), while 67% had partial responses (PR). For the rituximab combination arm 30% had CR and 50% had PR. Pharmacokinetic data from Part 1 showed that at cycle 2/day 1 mean duvelisib trough concentrations for obinutuzuamb and rituximab were 613 and 465 ng/ml, respectively: mean trough concentrations were comparable to monotherapy range. Plasma concentration analysis suggested no drug-drug interaction takes place when combining either of the drugs. The safety profile of the obinutuzuamb combination was favorable in both cases. For the combination with obinutuzumab rate of infection was 45% but all grade 1 to 2, for the rituximab combination the rate was 23% with only 1 grade 3 event of pneumocystis jirovecii pneumonia infection [&lt;ulink linkID="1771875" linkType="Reference"&gt;1771875&lt;/ulink&gt;], [&lt;ulink linkID="1771048" linkType="Reference"&gt;1771048&lt;/ulink&gt;]. Later in June 2016, following the termination of the collaboration with AbbVie, Infinity closed the trial for strategic reasons [&lt;ulink linkID="1776420" linkType="Reference"&gt;1776420&lt;/ulink&gt;]. In December 2016, further data were presented at the 58th ASH Annual Meeting and Exposition in San Diego, CA. Best overall response rates including complete and partial responses were 81, 23, and 58%, respectively, in duvelisib + obinutuzumab arm, and were 92, 22, and 70%, respectively, in duvelisib + rituximab arm [&lt;ulink linkID="1881617" linkType="Reference"&gt;1881617&lt;/ulink&gt;]. In June 2018, data from blood samples from healthy volunteers and FL patients treated in the CONTEMPO study were presented at the 23rd EHA Annual Congress held in Stockholm, Sweden and at  the 54th ASCO Annual Meeting held in Chicago, IL [&lt;ulink linkID="2061512" linkType="Reference"&gt;2061512&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Indolent Non-Hodgkin lymphoma&lt;/subtitle&gt;&lt;subtitle&gt;Phase III&lt;/subtitle&gt;In February 2016, the MFDS approved a randomized, double-blind phase III  trial of duvelisib and bendamustine in subjects with NHL   [&lt;ulink linkID="1731113" linkType="Reference"&gt;1731113&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;In December 2015, a phase III, double-blind, placebo-controlled study (&lt;ulink linkID="243163" linkType="Protocol"&gt;NCT02576275&lt;/ulink&gt;; BRAVURA) to evaluate the safety and efficacy of duvelisib plus &lt;ulink linkID="6736" linkType="Drug"&gt;rituximab&lt;/ulink&gt; and bendamustine compared with  placebo plus bendamustine in patients (estimated n = 600) with relapsed iNHL was initiated in the US. The primary endpoint was progression-free survival. At that time, Infinity planned to ask the FDA for advice on whether the study design would serve as a confirmatory study if the DYNAMO study  supported accelerated approval. However, in June 2016, following the termination of the collaboration with AbbVie, Infinity closed the trial for strategic reasons [&lt;ulink linkID="1700592" linkType="Reference"&gt;1700592&lt;/ulink&gt;], [&lt;ulink linkID="1776420" linkType="Reference"&gt;1776420&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Phase II&lt;/subtitle&gt;In May 2013, an open-label, multicenter, single-arm  phase II study (&lt;ulink linkID="141782" linkType="Protocol"&gt;NCT01882803&lt;/ulink&gt;; IPI-145-06; DYNAMO) was initiated in patients (n = 129) with refractory indolent NHL (follicular lymphoma, marginal zone lymphoma or SLL),  refractory to both &lt;ulink linkID="6736" linkType="Drug"&gt;rituximab&lt;/ulink&gt; and chemotherapy or radioimmunotherapy to evaluate the safety and efficacy of monotherapy duvelisib  (25 mg bid) [&lt;ulink linkID="1432768" linkType="Reference"&gt;1432768&lt;/ulink&gt;],  [&lt;ulink linkID="1443728" linkType="Reference"&gt;1443728&lt;/ulink&gt;], [&lt;ulink linkID="1518351" linkType="Reference"&gt;1518351&lt;/ulink&gt;]. The primary endpoint was the objective response rate. At that time, the trial was expected to complete in November 2017 [&lt;ulink linkID="1518351" linkType="Reference"&gt;1518351&lt;/ulink&gt;]. In February 2015, recruitment was ongoing in Belarus, Belgium, Bulgaria, Canada, Czech Republic, France, Georgia, Italy, Hungary, Spain and the UK [&lt;ulink linkID="1518351" linkType="Reference"&gt;1518351&lt;/ulink&gt;]. In September 2015, enrollment of 120 patients was completed [&lt;ulink linkID="1699126" linkType="Reference"&gt;1699126&lt;/ulink&gt;], [&lt;ulink linkID="1700592" linkType="Reference"&gt;1700592&lt;/ulink&gt;]. In June 2016, topline results from the 129-patient trial were reported. The primary endpoint was met with an overall response rate of 46% (all partial responses). The overall response rate was 41, 68 and 33% among patients with follicular lymphoma, SLL and marginal zone lymphoma, respectively. However, larger clinical benefit for iNHL patients had been anticipated [&lt;ulink linkID="1772437" linkType="Reference"&gt;1772437&lt;/ulink&gt;]. In December 2016, further results were presented at the 58th ASH Annual Meeting and Exposition in San Diego, CA. Median duration of response and median time to response was 9.9 and 1.9 months, respectively. During a median follow-up period of 11.5 months, median progression-free survival was 8.4 months and median overall survival was 18.4 months). Duvelisib treatment decreased tumor burden in 83% of patients. Adverse events (AEs) reported were predominantly of grade 1 to 2 in severity. Diarrhea, thrombocytopenia, anemia and neutropenia were the most commonly reported grade &amp;gt;/= 3 AEs [&lt;ulink linkID="1881695" linkType="Reference"&gt;1881695&lt;/ulink&gt;], [&lt;ulink linkID="1882364" linkType="Reference"&gt;1882364&lt;/ulink&gt;]. In June 2017, results from SLL patients  (n = 28) were presented at the 22nd EHA Annual Congress in Madrid, Spain. Overall response rate (ORR) assessed by independent review committee (IRC; primary endpoint), partial response rate per IRC, ORR per investigator, complete response rate per investigator and partial response rate per investigator was 68, 68, 86, 4 and 82%, respectively. Target nodal lesions decreased in all evaluable patients. Median duration of response, progression-free survival and  overall survival was 10.1, 11.7 and 28.9 months, respectively. Duvelisib had a manageable safety profile and remained well tolerated during long-term follow-up [&lt;ulink linkID="1939400" linkType="Reference"&gt;1939400&lt;/ulink&gt;], [&lt;ulink linkID="1929078" linkType="Reference"&gt;1929078&lt;/ulink&gt;], [&lt;ulink linkID="1940786" linkType="Reference"&gt;1940786&lt;/ulink&gt;]. Further data from 83 FL patients were presented at the same conference. The median duration of response among FL patients with response per independent review committe (n = 34) was 9.2 months; and the median PFS and OS was 8.3 and 11.1 months, respectively. Treated patients reported mostly adverse events (AEs) of grade 1-2. Transient cytopenias like neutropenia, anemia and thrombocytopenia (23, 12 and 10% of patients, respectively) and diarrhea (15% of patients) were the commonly reported AEs of grade &amp;gt;/= 3 [&lt;ulink linkID="1946205" linkType="Reference"&gt;1946205&lt;/ulink&gt;], [&lt;ulink linkID="1929078" linkType="Reference"&gt;1929078&lt;/ulink&gt;], [&lt;ulink linkID="1940786" linkType="Reference"&gt;1940786&lt;/ulink&gt;]. By August 2017, long term follow-up data had been presented at the 14th International Conference on Malignant Lymphoma which had demonstrated a durable 47% response rate and a manageable safety profile in patients with iNHL with 88% of patients experiencing a reduction in the size of target lymph nodes. The median duration of response, PFS and  OS was  10, 9 and 27.8 months respectively. The study mets its primary ORR endpoint at  p = 0.0001during the primary analysis  [&lt;ulink linkID="1951830" linkType="Reference"&gt;1951830&lt;/ulink&gt;], [&lt;ulink linkID="1952258" linkType="Reference"&gt;1952258&lt;/ulink&gt;]. By that time, the company had also presented further data on FL patients demonstrating an ORR of 43%, as determined by an independent review committee, with 83% of patients experiencing a reduction in the size of target lymph nodes. The median duration of response and  OS was  7.9 months and 27.8 months, respectively [&lt;ulink linkID="1951830" linkType="Reference"&gt;1951830&lt;/ulink&gt;].  In June 2018, further data were presented at the 54th ASCO Annual Meeting in Chicago, IL. Duvelisib treatment significantly decreased 17 serum factors when compared to baseline at cycle 1 day 15 (p&amp;lt;0.05); of these, all except TPO showed a significant change from baseline at cycle 2 day 1. Elevated levels of key serum factors (pretreatment) were observed in iNHL patients (n = 15) when compared with 15 healthy donors [&lt;ulink linkID="2039347" linkType="Reference"&gt;2039347&lt;/ulink&gt;].    Later that month, further data were presented at the 23rd EHA Annual Congress in Stockholm, Sweden. Many of the chemokines were inhibited following duvelisib treatment were associated with the tumor microenvironment (TME), including TNF-alpha, IL-10, IL2R-alpha, IL12P40, CCL1, CCL17, CCL19, CXCL9, CXCL10, CXCL11, and CXCL13. Corresponding 13 chemokines were also inhibited (p&amp;lt;/=0.008), including TME factors [&lt;ulink linkID="2045668" linkType="Reference"&gt;2045668&lt;/ulink&gt;], [&lt;ulink linkID="2045424" linkType="Reference"&gt;2045424&lt;/ulink&gt;]. In February 2019, data were published. Data demonstrated that duvelisib had an ORR of 47.3% (SLL, 67.9%; FL, 42.2%; MZL, 38.9%). The estimated median duration of response was 10 months, and the estimated median PFS was 9.5 months. Further, 88.4% of patients exhibited at least one grade 3 or greater TEAE [&lt;ulink linkID="2119909" linkType="Reference"&gt;2119909&lt;/ulink&gt;], [&lt;ulink linkID="2120262" linkType="Reference"&gt;2120262&lt;/ulink&gt;]. In March 2019, similar data were presented at the Annual International Congress on Hematologic Malignancies in Miami, FL [&lt;ulink linkID="2127249" linkType="Reference"&gt;2127249&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Miscellaneous phase I&lt;/subtitle&gt;In May 2016, an investigator-led, non-randomized, parallel assignment, dose escalation, open label, phase I trial (&lt;ulink linkID="261941" linkType="Protocol"&gt;NCT02783625&lt;/ulink&gt;; 16-042) was initiated in the US to evaluate the safety of duvelisib in combination with either &lt;ulink linkID="8023" linkType="Drug"&gt;romidepsin&lt;/ulink&gt; or &lt;ulink linkID="15954" linkType="Drug"&gt;bortezomib&lt;/ulink&gt; in patients (expected n = 88) with r/r T-cell lymphoma. At that time the study was expected to complete in May 2018 [&lt;ulink linkID="2030582" linkType="Reference"&gt;2030582&lt;/ulink&gt;]. In December 2017, results were presented at the American Society of Hematology 2017 Annual Meeting, demonstrating an   64% overall response rate, and a 34% complete response rate in the treatment group [&lt;ulink linkID="2091808" linkType="Reference"&gt;2091808&lt;/ulink&gt;]. In May 2018, data were reported showing that the combinations had an acceptable safety profile and  meaningful response rates [&lt;ulink linkID="2030492" linkType="Reference"&gt;2030492&lt;/ulink&gt;]. In December 2018, further data were presented at the 60th ASH Annual Meeting and Exposition in San Diego, CA. Patients received 3 + 3 escalating dose of duvelisib (25, 50 and 75 mg, po bid) with romidepsin (Arm A: 10 mg/m2, iv) or duvelisib (25, 50 and 75 mg, po, bid) with bortezomib (Arm B: 1 mg/m2, sc). In Arm A, at all dose levels, median PFS  was 5.41 and 6.72 months in CTCL and PTCL patients, respectively.  In Arm A, at all dose levels, median PFS was 4.56 and 4.39 months in CTCL and PTCL patients, respectively [&lt;ulink linkID="2098192" linkType="Reference"&gt;2098192&lt;/ulink&gt;], [&lt;ulink linkID="2101024" linkType="Reference"&gt;2101024&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In November 2015, AbbVie and Infinity initiated an open-label, phase I trial (&lt;ulink linkID="245348" linkType="Protocol"&gt;NCT02598570&lt;/ulink&gt;; M15-460) in Japan to evaluate the safety and pharmacokinetics ofÂ duvelisibÂ in Japanese patients (estimated n = 6) with relapsed or refractoryÂ lymphoma; at that time the trial was expected to complete in November 2016 [&lt;ulink linkID="1747936" linkType="Reference"&gt;1747936&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;May 2013, the company initiated a phase Ib, open-label, dose-escalation study  (&lt;ulink linkID="138164" linkType="Protocol"&gt;NCT01871675&lt;/ulink&gt;; SCRI HEMREF 34) designed to evaluate the safety, pharmacokinetics and clinical activity of duvelisib in combination with &lt;ulink linkID="6736" linkType="Drug"&gt;rituximab&lt;/ulink&gt;, &lt;ulink linkID="47000" linkType="Drug"&gt;bendamustine&lt;/ulink&gt; or both rituximab and bendamustine in B-cell NHL, CLL and T-cell lymphoma patients (n = approximately 70) was open for enrollment in the US [&lt;ulink linkID="1416791" linkType="Reference"&gt;1416791&lt;/ulink&gt;], [&lt;ulink linkID="1518342" linkType="Reference"&gt;1518342&lt;/ulink&gt;]. The primary endpoint was antitumor activity, assessed up to 5 years. At that time, the trial was expected to complete in December 2015 [&lt;ulink linkID="1518342" linkType="Reference"&gt;1518342&lt;/ulink&gt;]. In December 2015, further clinical data from the trial were presented at the 57th ASH Annual meeting and exposition in Orlando, FL. Patients were treated with duvelisib (25 to 75 mg, bid, po) in combination with rituximab (375 mg/m2, iv) in arm 1 (n = 28) and duvelisib in combination with bendamustine (90 mg/m2, iv) + rituximab in arm 2 (n = 19). DLT were not reported and MTD was not reached on any arm of the trial. Objective response rate was 87 and 79% and complete response, partial response, stable disease, and progressive disease were achieved by 13, 74, 9, and 4 and 14, 64, 7, and 14% of patients in arms 1 and 2, respectively. Median progression-free survival and median overall survival were not reached (both) in arm 1 and 9.1 months and not reached in arm 2, respectively [&lt;ulink linkID="1718960" linkType="Reference"&gt;1718960&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In October 2011, an open-label, dose-escalation, phase I trial (&lt;ulink linkID="82599" linkType="Protocol"&gt;NCT01476657&lt;/ulink&gt;; IPI-145-02) was initiated in patients (expected n = 200) in the US with advanced hematologic malignancies to assess the safety, efficacy and pharmacokinetics of duvelisib [&lt;ulink linkID="1234966" linkType="Reference"&gt;1234966&lt;/ulink&gt;], [&lt;ulink linkID="1353052" linkType="Reference"&gt;1353052&lt;/ulink&gt;]. At that time, the study was expected to complete in May 2014 [&lt;ulink linkID="1353052" linkType="Reference"&gt;1353052&lt;/ulink&gt;]. After the determination of the maximum tolerated dose in the dose-escalation phase, an expansion phase was expected  to follow in patients with selected hematologic malignancies [&lt;ulink linkID="1234966" linkType="Reference"&gt;1234966&lt;/ulink&gt;]. By July 2012, dose-escalation was ongoing, and  expansion cohorts had begun. Patients with CLL, indolent NHL or mantle cell lymphoma would receive 25 mg bid [&lt;ulink linkID="1309335" linkType="Reference"&gt;1309335&lt;/ulink&gt;]. In September 2012, data were presented from 55 patients at the 37th Annual IUGA Meeting in Brisbane, Australia. Of 41 patients evaluable for response, 3 showed complete response, 16 had PR, 11 showed stable disease and 11 had progressive disease. At all doses of duvelisib, reduction in tumor mass was observed. In CLL/SLL patients, the response rate was 82% after two cycles of duvelisib [&lt;ulink linkID="1346929" linkType="Reference"&gt;1346929&lt;/ulink&gt;]. In December 2012, the company reported preliminary data at the 54th ASH Annual Meeting   in Atlanta, Georgia. Duvelisib showed clinical activity at all doses (between 8 mg to 75 mg bid) and 75 mg bid was the MTD [&lt;ulink linkID="1388947" linkType="Reference"&gt;1388947&lt;/ulink&gt;]. By January 2013, 67% of patients were still receiving treatment and 90% of these patients did not have progressive disease after 2 cycles of treatment [&lt;ulink linkID="1355183" linkType="Reference"&gt;1355183&lt;/ulink&gt;].  The median time to response was 2 to 3 months [&lt;ulink linkID="1355183" linkType="Reference"&gt;1355183&lt;/ulink&gt;]. In March 2013, the company initiated five expansion cohorts of the trial [&lt;ulink linkID="1388947" linkType="Reference"&gt;1388947&lt;/ulink&gt;]. In June 2013, data were presented at the 12thÂ International Conference on Malignant Lymphoma in Lugano, Switzerland. Duvelisib was clinically active in patients with B-cell or T-cell malignancies. Median time to response was &amp;lt; 2 months. Of the 19 evaluable Hodgkin's lymphoma patients for response, 68% response rate, including 3 complete responses (CR) and 10 PR were reported, with a median time to response of 1.8 months. Of 22 evaluable CLL patients for response, a 55% response rate, including 12 PRs were observed, with a stable disease in 9 patients. The median time to response was 1.9 months. Response rate of 33%, with one CR and one PR, was observed in patients with T-cell lymphoma. Stable disease was reported in two patients with cutaneous T-cell lymphoma (CTCL) and the median time to response was 1.9 months [&lt;ulink linkID="1443728" linkType="Reference"&gt;1443728&lt;/ulink&gt;]. In June 2013, data were presented at the 49th ASCO Meeting in Chicago, IL. The MTD of duvelisib was 75 mg bid (primary endpoint). Of 22 evaluable CLL patients, the best partial response, nodal response (NR), stable disease and disease progression were observed in 12, 7, 2 and 1 patient(s), respectively. Dose-dependent increase in AUC was observed. The mean T1/2 of duvelisib at 25 and 75 mg bid was ranged from 4 to 5 h [&lt;ulink linkID="1427549" linkType="Reference"&gt;1427549&lt;/ulink&gt;].  In December 2013, further data were presented at the 55th ASH Meeting in New Orleans, LA. Nodal responses (&amp;gt; 50% reduction in adenopathy) were seen in 79% of patients after 2 treatment cycles. Best overall response rate (ORR) was 52%, with 1 CR, 15 PR, 14 stable diseases and 1 progressive disease. The ORR for the 19 evaluable patients receiving &amp;lt;/= 25 mg, bid doses was 53%. Relapsed/refractory patients with high-risk disease (TP53 mut/17pdel) showed similar ORR [&lt;ulink linkID="1503622" linkType="Reference"&gt;1503622&lt;/ulink&gt;]. The objective response rate in patients treated with &amp;lt;/= 25 mg bid doses of IPI-145 was 73%. Of the 15 iNHL patients, 8 patients were progression-free and 7 patients remained on study [&lt;ulink linkID="1503050" linkType="Reference"&gt;1503050&lt;/ulink&gt;] [&lt;ulink linkID="1507086" linkType="Reference"&gt;1507086&lt;/ulink&gt;]; further data showed that IPI-145 had nodal response rate of 89%  and an ORR rate of 48%, of the 27 CLL patients [&lt;ulink linkID="1528632" linkType="Reference"&gt;1528632&lt;/ulink&gt;]. In December 2013, results were presented for aggressive NHL patients enrolled in the trial at the 55th ASH Meeting in New Orleans, LA demonstrating IPI-145 showed reduction in adenopathy in 3 of 8 patients with DLBCL and in 2 of 3 patients with Richter transformation. Partial response (PR) was observed in 1 of 3 patients with transformed follicular lymphoma [&lt;ulink linkID="1528632" linkType="Reference"&gt;1528632&lt;/ulink&gt;]. In January 2014, data were presented at the 6th Annual T-Cell Lymphoma Forum  in San Francisco, CA, from 26 patients in the trial with T-cell lymphoma. The overall response rate was 38%, including one complete response and nice PRs. In 11 evaluable patients with PTCL, duvelisib led to one complete response and five PRs, for an overall response rate of 55%, and in 15 evaluable patients with CTCL,  duvelisib led to four PRs, for an overall response rate of 27%. The median time to response in PTCL and CTCL patients was 1.9 and 2.4 months, respectively [&lt;ulink linkID="1518220" linkType="Reference"&gt;1518220&lt;/ulink&gt;]. In September 2014, the trial was ongoing [&lt;ulink linkID="1590188" linkType="Reference"&gt;1590188&lt;/ulink&gt;]. In December 2014, further clinical data were presented at the 56th ASH Meeting in San, Francisco, CA. At all dose groups, complete response, partial response, stable disease and progressive response were seen in 1, 29, 21 and 1 patient, respectively; progression free survival was estimated to be 15.7 months and overall survival was not achieved. [&lt;ulink linkID="1618404" linkType="Reference"&gt;1618404&lt;/ulink&gt;], [&lt;ulink linkID="1619300" linkType="Reference"&gt;1619300&lt;/ulink&gt;]. At the same conference, further clinical data were presented. The ORR in PTCL and CTCL patients were 47 and 38%, respectively, and the median overall survival was 36.4 weeks. Overall, 79% of patients had &amp;gt;/= grade-3 adverse events and 3 patients died [&lt;ulink linkID="1618213" linkType="Reference"&gt;1618213&lt;/ulink&gt;], [&lt;ulink linkID="1619608" linkType="Reference"&gt;1619608&lt;/ulink&gt;]. Further clinical data were also  presented at  the same conference showing that duvelisib was found to be generally well tolerated with an acceptable safety profile across the dose range evaluated and with ORR of 65%. Increases were observed in AUC and Cmax values across the dose range evaluated [&lt;ulink linkID="1618212" linkType="Reference"&gt;1618212&lt;/ulink&gt;]. At the same conference, further clinical data were presented  showing that 40% of CLL patients had &amp;gt;/= 50% reduction in adenopathy. Partial response was achieved by one CLL patient and two NHL patients while stable disease was seen in five CLL patients and one NHL patients. Disease progression was seen in two NHL patients. Serious adverse events were reported in nine patients   [&lt;ulink linkID="1618405" linkType="Reference"&gt;1618405&lt;/ulink&gt;]. In May 2015, data from the trial were presented at the 51st ASCO meeting in Chicago, IL. Data demonstrated that 13 serum factors such as CXCL3, CCL3, CCL4, CCL22, CCL1, CCL17, CXCL10, IL-6, 1L-12-p40, MMP-9, and MMP-12, known to be involved in the communication between CLL cells and tumor microenvironment were decreased by duvelisib [&lt;ulink linkID="1662290" linkType="Reference"&gt;1662290&lt;/ulink&gt;], [&lt;ulink linkID="1664936" linkType="Reference"&gt;1664936&lt;/ulink&gt;]. Further data from the trial were presented at the same conference. Median progression free survival (PFS) and overall survival were not reached, however, PFS rate was 100 and 92% at 12 and 18 months, respectively and overall survival rate was 94% at 12 and 18% [&lt;ulink linkID="1662093" linkType="Reference"&gt;1662093&lt;/ulink&gt;], [&lt;ulink linkID="1664936" linkType="Reference"&gt;1664936&lt;/ulink&gt;]. In June 2015, clinical data  from an expansion cohort of treatment-naive CLL patients (n = 18) were presented at the 20th EHA Congress in Vienna, Austria. The best objective response rate was found to be 82%, with 14 partial responses   [&lt;ulink linkID="1670527" linkType="Reference"&gt;1670527&lt;/ulink&gt;]. In May 2018, data were reported from  16 heavily pre-treated patients with relapsed or refractory PTCL showing a 50% investigator-assessed ORR, including a 19% CR rate and a 31% PR rate [&lt;ulink linkID="2030492" linkType="Reference"&gt;2030492&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Inflammatory disease&lt;/subtitle&gt;In May 2013, Â a phase II, double-blind, parallel, placebo-controlled, randomized, ASPIRA trial (&lt;ulink linkID="130458" linkType="Protocol"&gt;NCT01851707&lt;/ulink&gt;; IPI-145-04)  was open for enrollment in patients (approximately n = 300) with RA [&lt;ulink linkID="1416791" linkType="Reference"&gt;1416791&lt;/ulink&gt;], [&lt;ulink linkID="1419612" linkType="Reference"&gt;1419612&lt;/ulink&gt;], [&lt;ulink linkID="1419612" linkType="Reference"&gt;1419612&lt;/ulink&gt;], [&lt;ulink linkID="1419618" linkType="Reference"&gt;1419618&lt;/ulink&gt;]. In January 2015, topline data from the 332-patient trial were reported. The trial did not meet its primary endpoint of a 20% improvement in American College of Rheumatology (ACR20) response at 12 weeks with any of the doses assessed in the trial (0.5, 1 and 5 mg bid + methotrexate) compared with placebo. At that time, Infinity discontinued further clinical development in RA [&lt;ulink linkID="1625120" linkType="Reference"&gt;1625120&lt;/ulink&gt;]. In November 2015, further data were presented at the 79th ACR Annual Meeting in San Francisco, CA. At week 12, American College of Rheumatology 20% improvementÂ criteria (primary endpoint) and least square mean change from baseline disease activity score 28-C-reactive protein for placebo, 0.5, 1 and 5 mg doses of duvelisib were 46.3% and -1.28, 51.9% and -1.66, 45.0% and -1.36, and 43.2% and -1.68, respectively. Overall, duvelisib administration with background methotrexate in adults with moderate to severe rheumatoid arthritis showed no added benefit compared with placebo and there were no new drug-related safety signals [&lt;ulink linkID="1709568" linkType="Reference"&gt;1709568&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In July 2012, a phase IIa, randomized, double-blind, placebo-controlled, crossover study (&lt;ulink linkID="89714" linkType="Protocol"&gt;NCT01653756&lt;/ulink&gt;; IPI-145-03, 2012-001729-28) was initiated in UK, to evaluate the safety and efficacy of multiple doses of duvelisib in mild asthmatic patients (estimated n = 30) undergoing allergen challenge. Recruitment was expected to be initiated in Germany. The primary endpoint was Forced Expiratory Volume in 1 sec (FEV1). At that time, the study was expected to complete in September 2013 [&lt;ulink linkID="1312702" linkType="Reference"&gt;1312702&lt;/ulink&gt;]. In September 2014, the trial completed [&lt;ulink linkID="1312702" linkType="Reference"&gt;1312702&lt;/ulink&gt;], In October 2014, topline data were reported, demonstrating that the primary endpoint was not met but that several secondary and exploratory endpoints were met. At the highest dose (25 mg bid for 5 days), clinical improvement in late-phase asthmatic response FEV1 was observed, but was not significantly different from placebo. Secondary endpoints measuring improvements in lung function achieved significance compared with placebo, and the 5- and 25-mg bid doses significantly decreased serum levels of key cytokines and chemokines involved in the asthmatic response [&lt;ulink linkID="1602792" linkType="Reference"&gt;1602792&lt;/ulink&gt;].  In September 2015, similar data were presented at the 25th ERS Congress in Amsterdam, the Netherlands [&lt;ulink linkID="1699925" linkType="Reference"&gt;1699925&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;By October 2011, the company had filed an IND and a  clinical trial application  with an European national regulatory authority [&lt;ulink linkID="1229956" linkType="Reference"&gt;1229956&lt;/ulink&gt;].      &lt;/para&gt;&lt;para&gt;In January 2009, an IND candidate was expected to be selected in the first half of 2009 [&lt;ulink linkID="980315" linkType="Reference"&gt;980315&lt;/ulink&gt;]. In October 2011, a double-blind, randomized, placebo-controlled, phase I trial was initiated  in healthy volunteers  to assess safety, tolerability, pharmacokinetics and pharmacodynamics  of single and multiple escalating doses of duvelisib [&lt;ulink linkID="1234966" linkType="Reference"&gt;1234966&lt;/ulink&gt;]. In March 2012, the trial (&lt;ulink linkID="85775" linkType="Protocol"&gt;NCT01549106&lt;/ulink&gt;, IPI-145-01, 2011-001944-31) was completed in 106 healthy volunteers [&lt;ulink linkID="1301999" linkType="Reference"&gt;1301999&lt;/ulink&gt;], [&lt;ulink linkID="1301837" linkType="Reference"&gt;1301837&lt;/ulink&gt;]. In June 2012, it was reported that the drug was safe and well tolerated [&lt;ulink linkID="1304854" linkType="Reference"&gt;1304854&lt;/ulink&gt;]. In November 2012, data were presented at the ACR/ARHP   Annual Meeting in Washington, DC.  In the study, pharmacokinetic data showed that  duvelisib was rapidly and dose-proportionally absorbed. The compound had a half-life of 7 to 12 h, with or without food,   consistent with  bid dosing  [&lt;ulink linkID="1338055" linkType="Reference"&gt;1338055&lt;/ulink&gt;], [&lt;ulink linkID="1339860" linkType="Reference"&gt;1339860&lt;/ulink&gt;], [&lt;ulink linkID="1342106" linkType="Reference"&gt;1342106&lt;/ulink&gt;]. In September 2016, further clinical data were presented at the 2016 Annual Meeting of the ACCP in Bethesda, MD. Exposure  increased in dose-proportional manner. The t1/2 was approximately 4 to 10 h after single dose administration and approximately 7 to 12 h after   multiple dose administration. Median Tmax was delayed by 1 to 3 h on intake of high fat meal, but overall exposure was not appreciably affected. A correlation was observed between duvelisib pharmacodynamics effects and duvelisib plasma concentrations, with increased pharmacodynamics effects observed at higher concentrations. Across the single- and multiple-dose range evaluated, duvelisib was well tolerated with the majority of adverse events assessed as mild [&lt;ulink linkID="1894938" linkType="Reference"&gt;1894938&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Other studies&lt;/subtitle&gt;In May 2019, an IND was filed in China [&lt;ulink linkID="2148060" linkType="Reference"&gt;2148060&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In December 2018, data from four clinical studies (phase I: NCT01476657 [IPI-145-02], phase II: NCT01882803 [IPI-145-06; DYNAMO], and phase III:  [IPI-145-07; DUO] and NCT02049515 [IPI-145-12])which evaluated the long-term (&amp;gt; 2 years) efficacy and safety of duvelisib in patients with relapsed/refractory CLL/SLL were presented at the 60th ASH Annual Meeting and Exposition in San Diego, CA. Among all patients and patients with del(17p)/TP53 mutation (n = 46 and 10, respectively), the ORR was 89 and 100%, respectively; CR/CRi was achieved by 9 and 3 patients, respectively; PR was achieved by 32 and 7 patients, respectively; SD was observed in 5 and 0 patients, respectively; lymph node response rate was 87 and 80%, respectively; and median PFS was 40 and 38 months, respectively. . The AE profile of patients who received duvelisib &amp;gt; 2 years was similar to those who received duvelisib &amp;lt; 2 years [&lt;ulink linkID="2098145" linkType="Reference"&gt;2098145&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;In January 2015, the company planned to initiate a study of duvelisib in combination with &lt;ulink linkID="70895" linkType="Drug"&gt;venetoclax&lt;/ulink&gt; later that year [&lt;ulink linkID="1625918" linkType="Reference"&gt;1625918&lt;/ulink&gt;]. In October 2015, Infinity anticipated that AbbVie would initiate the phase Ib/II trial in hematologic malignancies [&lt;ulink linkID="1700592" linkType="Reference"&gt;1700592&lt;/ulink&gt;].  In January 2016, the trial was expected to begin   that month. The trial was to be conducted in patients (n = 174) with relapsed or refractory CLL, small lymphocytic lymphoma, indolent NHL or aggressive NHL [&lt;ulink linkID="1726217" linkType="Reference"&gt;1726217&lt;/ulink&gt;]. Later that month, AbbVie noted the study would be a dose-finding study [&lt;ulink linkID="1732230" linkType="Reference"&gt;1732230&lt;/ulink&gt;].  By February 2016, the trial had been initiated [&lt;ulink linkID="1737218" linkType="Reference"&gt;1737218&lt;/ulink&gt;]. In June 2016, subject to ongoing collaborative business discussions, AbbVie and infinity agreed to pause the trial [&lt;ulink linkID="1772437" linkType="Reference"&gt;1772437&lt;/ulink&gt;]. Later in June 2016, following the termination of the collaboration with AbbVie, Infinity closed the trial for strategic reasons [&lt;ulink linkID="1776420" linkType="Reference"&gt;1776420&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;Also in January 2015, the company  planned to initiate two additional studies as part of a further expansion of the DUETTS program [&lt;ulink linkID="1625918" linkType="Reference"&gt;1625918&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In March 2014, an open label, phase I trial (&lt;ulink linkID="179359" linkType="Protocol"&gt;NCT02095587&lt;/ulink&gt;; IPI-145-14) was initiated in the US to evaluate pharmacokinetics, safety, and tolerability of a single dose of IPI-145 in patients (expected n = 24) with chronic hepatic impairment, compared to healthy subjects. The trial was expected to be completed in December 2014 [&lt;ulink linkID="1545070" linkType="Reference"&gt;1545070&lt;/ulink&gt;].&lt;/para&gt;&lt;/Premarketing&gt;</value></Premarketing><Preclinical><displayLabel>Preclinical</displayLabel><value>&lt;Preclinical&gt;&lt;para&gt;In December 2018, preclinical data were presented at the 60th ASH Annual Meeting and Exposition in San Diego, CA. In NSG mice injected with activated T cells and CLL B cells from patients who progressed on ibrutinib (one with a BTK C481S mutation and one without a BTK mutation), duvelisib treatment for 3 weeks led to a &amp;gt; 10-fold reduction in the number of CLL B cells recovered from the spleens and also led to significant reduction in the percentage of proliferating CLL B cells. In contrast, ibrutinib showed no significant impact on CLL B-cell numbers or proliferation in the spleen  [&lt;ulink linkID="2098841" linkType="Reference"&gt;2098841&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;In June 2018, in vitro data were presented at the 23rd EHA Annual Congress in Stockholm, Sweden. Duvelisib and idelalisib potently inhibited LPS-induced human monocytes with IC50 values of 0.4 and 1 mM, respectively, via P13 K-delta when compared with P13 K-gamma selective IPI-549 (IC50 12 mM) [&lt;ulink linkID="2045689" linkType="Reference"&gt;2045689&lt;/ulink&gt;], [&lt;ulink linkID="2045424" linkType="Reference"&gt;2045424&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In June 2018, in vitro data were presented at the 54th ASCO Annual Meeting in Chicago, IL.  Ex vivo whole blood assays revealed that duvelisib 25 mg (bid) inhibited PI3K-delta and gamma at 1 to 4 h post dose. Duvelisib inhibited macrophage polarization, reduced CXCL 12-induced macrophage migration, blocked CXCL 12-induced T cell migration. Duvelisib and IPI-549 showed comparable inhibitor activities [&lt;ulink linkID="2039339" linkType="Reference"&gt;2039339&lt;/ulink&gt;] [&lt;ulink linkID="2034966" linkType="Reference"&gt;2034966&lt;/ulink&gt;]  and [&lt;ulink linkID="2041304" linkType="Reference"&gt;2041304&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In May 2018, data on the preclinical models of both hematological malignancies and solid tumors to enhance the efficacy of immune checkpoint and co-stimulatory antibodies were  presented at the 3rd annual Advances in Immuno-Oncology Congress held in London, England [&lt;ulink linkID="2061512" linkType="Reference"&gt;2061512&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In December 2017, preclinical data were presented at the 59th ASH Annual Meeting and Exposition in Atlanta, GA. In mice bearing syngeneic A20B cell lymphoma tumors, treatment with duvelisib (50 mg/kg, bid, po) + anti-PD-1 (clone RMP1-14, 100 mg/mouse, ip, biw x 2) resulted in synergistic induction of tumor growth inhibition and survival. Duvelisib (50 mg/kg, bid, po) + anti-OX40 (clone OX86, 100 mg/mouse, ip, biw x 2) induced tumor regressions, immune memory and long term survival in A20 B cell lymphoma bearing mice  [&lt;ulink linkID="1989013" linkType="Reference"&gt;1989013&lt;/ulink&gt;] [&lt;ulink linkID="1988152" linkType="Reference"&gt;1988152&lt;/ulink&gt;]. In January 2018, similar preclinical data were presented at ASCO-SITC Clinical Immuno-Oncology Symposium in San Francisco, CA [&lt;ulink linkID="2000382" linkType="Reference"&gt;2000382&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In December 2016, preclinical data were presented at the 58th ASH Annual Meeting and Exposition in San Diego, CA. In a murine CLL model, plasma concentrations were achieved, CLL disease burden was reduced, and CD4/CD8 and Th1/Th2 T cell ratios were returned to normal after po TGR-1202 or duvelisib treatment. In mice treated with po TGR-1202, total regulatory T cells number, total Th17 number, and regulatory T cells/Th17 ratios were preserved and the number of programmed death-1 expressing regulatory T cells and IL-10 secretion from CD3+ CLL T cells were maintained [&lt;ulink linkID="1881229" linkType="Reference"&gt;1881229&lt;/ulink&gt;]. Further preclinical data were presented at the same conference. Significantly inhibited tumor growth and prolonged survival of mantle cell lymphoma (MCL)-PDX mice was observed with duvelisib (50 mg/kg, qd, po) treatment. In vitro and in PDX mice, treatment with duvelisib showed inhibition of MCL growth [&lt;ulink linkID="1881505" linkType="Reference"&gt;1881505&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In April 2016, preclinical data were presented at the 107th AACR Annual Meeting in New Orleans, LA, USA. IC50 values for isoforms PI3K-sigma and gamma were 0.4 and 20 nM respectively in RAJI and RAW 264.7 cell lines. In aggressive lymphoma cell lines, duvelisib synergizes in vitro with dexamethasone and &lt;ulink linkID="55237" linkType="Drug"&gt;ibrutinib&lt;/ulink&gt;. Quantitation of ATP after 72 h assessed dose matrices growth inhibition as complete with GI value of 100 and cell death with values between 100 to 200. There was greater tumor growth inhibition observed by combination of duvelisib with dexamethasone or ibrutinib than monotherapy [&lt;ulink linkID="1755083" linkType="Reference"&gt;1755083&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;In December 2015, preclinical data were presented at the 57th ASH Annual Meeting and Exposition in Orlando, FL. Duvelisib (100 mg/kg) significantly inhibited the CLL B-cell growth, survival and proliferation in a murine xenograft model of CLL [&lt;ulink linkID="1718522" linkType="Reference"&gt;1718522&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt; In May 2015, preclinical data were presented at the 51st ASCO meeting in Chicago, IL. Median growth inhibition was 0.59 microM. Data demonstrated that dual inhibition of PI3K delta and gamma with duvelisib led to complementary effects on limiting malignant B cell growth and survival. In vitro synergy was observed between duvelisib + dexamethasone or ibrutinib or venetoclax in multiple cells lines [&lt;ulink linkID="1663626" linkType="Reference"&gt;1663626&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In December 2014, preclinical data were presented at the 56th ASH Meeting in San Francisco, CA. In primary CLL cells, duvelisib antagonized B-cell receptor derived survival signals and showed potent cytotoxic activity [&lt;ulink linkID="1618398" linkType="Reference"&gt;1618398&lt;/ulink&gt;]. Further preclinical data were also presented at this conference showing that duvelisib was found to inhibit CD40L/IL-2/IL-10-induced proliferation of primary CLL cells  and more potently inhibited CXCL12-induced phosphorylated AKT in M2 cells which express CXCR4 [&lt;ulink linkID="1619734" linkType="Reference"&gt;1619734&lt;/ulink&gt;], [&lt;ulink linkID="1619300" linkType="Reference"&gt;1619300&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In December 2013, preclinical data were presented at the 55th ASH Meeting in New Orleans, LA.    IPI-145 treatment resulted in down-regulation of p-AKT and p-ERK in sensitive diffuse large B-cell lymphoma (DLBCL) cell lines. In some DLBCL cell lines, IPI-145 showed synergistic activity when combined with &lt;ulink linkID="55237" linkType="Drug"&gt;ibrutinib&lt;/ulink&gt; [&lt;ulink linkID="1503132" linkType="Reference"&gt;1503132&lt;/ulink&gt;], [&lt;ulink linkID="1507087" linkType="Reference"&gt;1507087&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In December 2013, preclinical data were presented at the 55th ASH Meeting in New Orleans, LA. In murine phosphatase and tensin homolog (Pten)-deficient T-ALL cell lines, IPI-145 showed growth inhibition with IC50 values in the range of 327 to 599 nM; it showed down-regulation of pAkt, Notch-1 and c-Myc expression in a dose-responsive manner. In LOUCY  human T-ALL cell line, IPI-145 showed increased growth suppression when compared with either of the isoforms alone [&lt;ulink linkID="1502579" linkType="Reference"&gt;1502579&lt;/ulink&gt;] [&lt;ulink linkID="1507087" linkType="Reference"&gt;1507087&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In December 2013, data were presented at the 55th ASH Meeting in New Orleans, LA. In primary CLL cells, IPI-145 (1 microM) induced apoptosis and overcame stromal- and B-cell antigen receptor-mediated survival signals. IPI-145 potently inhibited CD40L-, IL-2-, IL-10-induced CLL cell proliferation with an IC50 value of 0.16 nM.  IPI-145 induced reactive oxygen species production in CLL primary cells [&lt;ulink linkID="1504329" linkType="Reference"&gt;1504329&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In April 2013, preclinical data were presented at the 245th ACS Meeting in New Orleans, LA. The anti-Fc epsilon receptor 1 antibody was inhibited by duvelisib5. In inflammation models of rheumatoid arthritis and Crohn's disease, duvelisib was found to be active. In a rat model of collagen-induced arthritis, a dose-dependent effect was shown by duvelisib [&lt;ulink linkID="1391791" linkType="Reference"&gt;1391791&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In November 2012, preclinical   data were presented at the ACR/ARHP  Annual Meeting in Washington, DC. In the study, duvelisib was shown to be effective at reducing inflammation in animal models of rheumatoid arthritis [&lt;ulink linkID="1339860" linkType="Reference"&gt;1339860&lt;/ulink&gt;], [&lt;ulink linkID="1342106" linkType="Reference"&gt;1342106&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In July 2012, it was reported that duvelisib demonstrated picomolar affinity for PI3Kdelta and gamma in vitro, potent isoform-specific activity in  cellular and whole blood assays, and high selectivity for PI3K  compared with other lipid and protein kinases. Duvelisib also demonstrated in vivo activity in models of collagen- and adjuvant-induced arthritis, Crohn's disease, systemic lupus erythematosus and multiple sclerosis [&lt;ulink linkID="1304854" linkType="Reference"&gt;1304854&lt;/ulink&gt;].  In January 2013, similar preclinical data were presented at the 31st Annual JPMorgan Healthcare Conference in San Francisco, CA [&lt;ulink linkID="1355183" linkType="Reference"&gt;1355183&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;By July 2010, it was reported that duvelisib had demonstrated  activity in rheumatoid arthritis, allergy and inflammation preclinical  models [&lt;ulink linkID="1115086" linkType="Reference"&gt;1115086&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;In April 2010, preclinical data were presented at the 101st AACR meeting in Washington DC. Selective PI3K pathway inhibition with INK-713 and INK-1048 resulted in cytostatic, and at higher concentrations cytotoxic, responses in hematological cancer cell lines [&lt;ulink linkID="1088894" linkType="Reference"&gt;1088894&lt;/ulink&gt;].  &lt;/para&gt;&lt;para&gt;In October 2009, data on the effect of duvelisib in a murine model of collagen-induced arthritis were presented at the ACR/ARHP annual meeting. INK-055 (30 or 60 mg/kg) had a prophylactic effect, significantly decreasing disease severity by day 32 when treatment was initiated at day 20, and was also effective in established disease, as it significantly decreased disease severity when treatment was initiated at day 30 [&lt;ulink linkID="1051155" linkType="Reference"&gt;1051155&lt;/ulink&gt;].  &lt;/para&gt;&lt;para&gt;In May 2009, the drug was listed as being in lead optimization for respiratory disease [&lt;ulink linkID="1010606" linkType="Reference"&gt;1010606&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;By January 2009, lead compounds   suitable for once daily dosing  had shown efficacy in multiple inflammatory models [&lt;ulink linkID="980315" linkType="Reference"&gt;980315&lt;/ulink&gt;]. &lt;/para&gt;&lt;/Preclinical&gt;</value></Preclinical><AdditionalInformation><displayLabel>Additional Information</displayLabel><value>&lt;AdditionalInformation&gt;&lt;para&gt;In September 2014, Infinity signed a master clinical supply agreement with &lt;ulink linkID="19446" linkType="Company"&gt;Roche&lt;/ulink&gt; to supply  &lt;ulink linkID="53227" linkType="Drug"&gt;obinutuzumab&lt;/ulink&gt; for use in clinical studies to evaluate the combination of obinutuzumab plus duvelisib in hematologic malignancies, including indolent NHL [&lt;ulink linkID="1590188" linkType="Reference"&gt;1590188&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In February 2016, Infinity awarded the &lt;ulink linkID="1041750" linkType="Company"&gt;National Comprehensive Cancer Network&lt;/ulink&gt;  (NCCN) Oncology Research Program a $2 million grant  to evaluate the safety and efficacy of duvelisib in hematologic malignancies; the NCCN planned to use the grant to support investigator-initiated clinical and correlative studies at NCCN member institutions  [&lt;ulink linkID="1733713" linkType="Reference"&gt;1733713&lt;/ulink&gt;].&lt;/para&gt;&lt;/AdditionalInformation&gt;</value></AdditionalInformation></DevelopmentProfile><IDdbDevelopmentStatus><DevelopmentStatusCurrent><Company id="1058061">Verastem Oncology</Company><Country id="US">US</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="1745">Follicle center lymphoma</Indication><StatusDate>2018-09-24T00:00:00.000Z</StatusDate><Source id="2075937" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1058061">Verastem Oncology</Company><Country id="US">US</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="1734">Chronic lymphocytic leukemia</Indication><StatusDate>2018-09-24T00:00:00.000Z</StatusDate><Source id="2075937" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1058061">Verastem Oncology</Company><Country id="AU">Australia</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="1734">Chronic lymphocytic leukemia</Indication><StatusDate>2016-11-02T00:00:00.000Z</StatusDate><Source id="1869112" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1058061">Verastem Oncology</Company><Country id="X5">Europe</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="311">T-cell lymphoma</Indication><StatusDate>2016-11-02T00:00:00.000Z</StatusDate><Source id="1869112" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1058061">Verastem Oncology</Company><Country id="X5">Europe</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="1734">Chronic lymphocytic leukemia</Indication><StatusDate>2016-11-02T00:00:00.000Z</StatusDate><Source id="1869112" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1058061">Verastem Oncology</Company><Country id="X5">Europe</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="1753">Peripheral T-cell lymphoma</Indication><StatusDate>2018-05-03T00:00:00.000Z</StatusDate><Source id="2030492" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1058061">Verastem Oncology</Company><Country id="CA">Canada</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="319">Non-Hodgkin lymphoma</Indication><StatusDate>2016-11-02T00:00:00.000Z</StatusDate><Source id="1869112" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="20961">Yakult Honsha Co Ltd</Company><Country id="JP">Japan</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="2054">Hematological neoplasm</Indication><StatusDate>2018-06-05T00:00:00.000Z</StatusDate><Source id="2041310" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1058061">Verastem Oncology</Company><Country id="X5">Europe</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="319">Non-Hodgkin lymphoma</Indication><StatusDate>2016-11-02T00:00:00.000Z</StatusDate><Source id="1869112" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1058061">Verastem Oncology</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="1753">Peripheral T-cell lymphoma</Indication><StatusDate>2018-02-22T00:00:00.000Z</StatusDate><Source id="1994404" type="TRIALREG"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="20961">Yakult Honsha Co Ltd</Company><Country id="JP">Japan</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="1753">Peripheral T-cell lymphoma</Indication><StatusDate>2018-06-05T00:00:00.000Z</StatusDate><Source id="2041310" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1058061">Verastem Oncology</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="319">Non-Hodgkin lymphoma</Indication><StatusDate>2016-11-02T00:00:00.000Z</StatusDate><Source id="1869112" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="20961">Yakult Honsha Co Ltd</Company><Country id="JP">Japan</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="203">Lymphoma</Indication><StatusDate>2018-06-05T00:00:00.000Z</StatusDate><Source id="2041310" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1058061">Verastem Oncology</Company><Country id="CA">Canada</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="1734">Chronic lymphocytic leukemia</Indication><StatusDate>2016-11-02T00:00:00.000Z</StatusDate><Source id="1869112" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1058061">Verastem Oncology</Company><Country id="US">US</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="311">T-cell lymphoma</Indication><StatusDate>2016-11-02T00:00:00.000Z</StatusDate><Source id="1869112" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1033194">CSPC Pharmaceuticals Group Limited</Company><Country id="HK">Hong Kong</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="651">Cancer</Indication><StatusDate>2018-09-25T00:00:00.000Z</StatusDate><Source id="2076090" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1033194">CSPC Pharmaceuticals Group Limited</Company><Country id="CN">China</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="651">Cancer</Indication><StatusDate>2018-09-25T00:00:00.000Z</StatusDate><Source id="2076090" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1033194">CSPC Pharmaceuticals Group Limited</Company><Country id="MO">Macau</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="651">Cancer</Indication><StatusDate>2018-09-25T00:00:00.000Z</StatusDate><Source id="2076090" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1033194">CSPC Pharmaceuticals Group Limited</Company><Country id="TW">Taiwan</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="651">Cancer</Indication><StatusDate>2018-09-25T00:00:00.000Z</StatusDate><Source id="2076090" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1045514">Mundipharma International Corp Ltd</Company><Country id="GB">UK</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="6">Deal Termination/Company Bankruptcy</DiscontinuedReason><Indication id="188">Inflammatory disease</Indication><StatusDate>2012-07-18T00:00:00.000Z</StatusDate><Source id="1309335" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="29753">Infinity Pharmaceuticals Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="2">Lack of Activity or Efficacy</DiscontinuedReason><Indication id="31">Asthma</Indication><StatusDate>2015-02-24T00:00:00.000Z</StatusDate><Source id="1641884" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="29753">Infinity Pharmaceuticals Inc</Company><Country id="NZ">New Zealand</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="5">Other</DiscontinuedReason><Indication id="1745">Follicle center lymphoma</Indication><StatusDate>2016-02-23T00:00:00.000Z</StatusDate><Source id="1737249" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="29753">Infinity Pharmaceuticals Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="2">Lack of Activity or Efficacy</DiscontinuedReason><Indication id="291">Rheumatoid arthritis</Indication><StatusDate>2015-01-08T00:00:00.000Z</StatusDate><Source id="1625120" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1045514">Mundipharma International Corp Ltd</Company><Country id="GB">UK</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="6">Deal Termination/Company Bankruptcy</DiscontinuedReason><Indication id="2054">Hematological neoplasm</Indication><StatusDate>2012-07-18T00:00:00.000Z</StatusDate><Source id="1309335" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1072507">AbbVie Inc</Company><Country id="JP">Japan</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="6">Deal Termination/Company Bankruptcy</DiscontinuedReason><Indication id="2054">Hematological neoplasm</Indication><StatusDate>2016-06-28T00:00:00.000Z</StatusDate><Source id="1776420" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="29753">Infinity Pharmaceuticals Inc</Company><Country id="CA">Canada</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="5">Other</DiscontinuedReason><Indication id="1745">Follicle center lymphoma</Indication><StatusDate>2016-02-23T00:00:00.000Z</StatusDate><Source id="1737249" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="29753">Infinity Pharmaceuticals Inc</Company><Country id="X5">Europe</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="5">Other</DiscontinuedReason><Indication id="1745">Follicle center lymphoma</Indication><StatusDate>2016-02-23T00:00:00.000Z</StatusDate><Source id="1737249" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="29753">Infinity Pharmaceuticals Inc</Company><Country id="AU">Australia</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="5">Other</DiscontinuedReason><Indication id="1745">Follicle center lymphoma</Indication><StatusDate>2016-02-23T00:00:00.000Z</StatusDate><Source id="1737249" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1072507">AbbVie Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="6">Deal Termination/Company Bankruptcy</DiscontinuedReason><Indication id="651">Cancer</Indication><StatusDate>2016-06-28T00:00:00.000Z</StatusDate><Source id="1776420" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1072507">AbbVie Inc</Company><Country id="JP">Japan</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="6">Deal Termination/Company Bankruptcy</DiscontinuedReason><Indication id="203">Lymphoma</Indication><StatusDate>2016-06-28T00:00:00.000Z</StatusDate><Source id="1776420" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1058061">Verastem Oncology</Company><Country id="MO">Macau</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="651">Cancer</Indication><StatusDate>2018-09-25T00:00:00.000Z</StatusDate><Source id="2076090" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="29753">Infinity Pharmaceuticals Inc</Company><Country id="JP">Japan</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="2054">Hematological neoplasm</Indication><StatusDate>2016-11-02T00:00:00.000Z</StatusDate><Source id="1869112" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="29753">Infinity Pharmaceuticals Inc</Company><Country id="X5">Europe</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="319">Non-Hodgkin lymphoma</Indication><StatusDate>2016-11-02T00:00:00.000Z</StatusDate><Source id="1869112" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1058061">Verastem Oncology</Company><Country id="JP">Japan</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="2054">Hematological neoplasm</Indication><StatusDate>2018-06-05T00:00:00.000Z</StatusDate><Source id="2041310" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="29753">Infinity Pharmaceuticals Inc</Company><Country id="US">US</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="1745">Follicle center lymphoma</Indication><StatusDate>2016-11-02T00:00:00.000Z</StatusDate><Source id="1869112" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="29753">Infinity Pharmaceuticals Inc</Company><Country id="US">US</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="188">Inflammatory disease</Indication><StatusDate>2016-11-02T00:00:00.000Z</StatusDate><Source id="1869112" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="29753">Infinity Pharmaceuticals Inc</Company><Country id="US">US</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="1734">Chronic lymphocytic leukemia</Indication><StatusDate>2016-11-02T00:00:00.000Z</StatusDate><Source id="1869112" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="29753">Infinity Pharmaceuticals Inc</Company><Country id="NZ">New Zealand</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="1734">Chronic lymphocytic leukemia</Indication><StatusDate>2016-11-02T00:00:00.000Z</StatusDate><Source id="1869112" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="29753">Infinity Pharmaceuticals Inc</Company><Country id="CA">Canada</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="1734">Chronic lymphocytic leukemia</Indication><StatusDate>2016-11-02T00:00:00.000Z</StatusDate><Source id="1869112" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="29753">Infinity Pharmaceuticals Inc</Company><Country id="AU">Australia</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="1734">Chronic lymphocytic leukemia</Indication><StatusDate>2016-11-02T00:00:00.000Z</StatusDate><Source id="1869112" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1058061">Verastem Oncology</Company><Country id="JP">Japan</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="203">Lymphoma</Indication><StatusDate>2018-06-05T00:00:00.000Z</StatusDate><Source id="2041310" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1058061">Verastem Oncology</Company><Country id="JP">Japan</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="1753">Peripheral T-cell lymphoma</Indication><StatusDate>2018-06-05T00:00:00.000Z</StatusDate><Source id="2041310" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1058061">Verastem Oncology</Company><Country id="CN">China</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="651">Cancer</Indication><StatusDate>2018-09-25T00:00:00.000Z</StatusDate><Source id="2076090" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1058061">Verastem Oncology</Company><Country id="HK">Hong Kong</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="651">Cancer</Indication><StatusDate>2018-09-25T00:00:00.000Z</StatusDate><Source id="2076090" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1045250">Intellikine Inc</Company><Country id="US">US</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="188">Inflammatory disease</Indication><StatusDate>2010-07-08T00:00:00.000Z</StatusDate><Source id="1115086" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="29753">Infinity Pharmaceuticals Inc</Company><Country id="US">US</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="319">Non-Hodgkin lymphoma</Indication><StatusDate>2016-11-02T00:00:00.000Z</StatusDate><Source id="1869112" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="29753">Infinity Pharmaceuticals Inc</Company><Country id="CA">Canada</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="319">Non-Hodgkin lymphoma</Indication><StatusDate>2016-11-02T00:00:00.000Z</StatusDate><Source id="1869112" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="29753">Infinity Pharmaceuticals Inc</Company><Country id="US">US</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="1754">Cutaneous T-cell lymphoma</Indication><StatusDate>2016-11-02T00:00:00.000Z</StatusDate><Source id="1869112" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="29753">Infinity Pharmaceuticals Inc</Company><Country id="JP">Japan</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="203">Lymphoma</Indication><StatusDate>2016-11-02T00:00:00.000Z</StatusDate><Source id="1869112" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1045250">Intellikine Inc</Company><Country id="US">US</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="2054">Hematological neoplasm</Indication><StatusDate>2010-07-08T00:00:00.000Z</StatusDate><Source id="1115086" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="29753">Infinity Pharmaceuticals Inc</Company><Country id="X5">Europe</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="1734">Chronic lymphocytic leukemia</Indication><StatusDate>2016-11-02T00:00:00.000Z</StatusDate><Source id="1869112" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1058061">Verastem Oncology</Company><Country id="TW">Taiwan</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="651">Cancer</Indication><StatusDate>2018-09-25T00:00:00.000Z</StatusDate><Source id="2076090" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="29753">Infinity Pharmaceuticals Inc</Company><Country id="GB">UK</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="1734">Chronic lymphocytic leukemia</Indication><StatusDate>2016-11-02T00:00:00.000Z</StatusDate><Source id="1869112" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="29753">Infinity Pharmaceuticals Inc</Company><Country id="US">US</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="1753">Peripheral T-cell lymphoma</Indication><StatusDate>2016-11-02T00:00:00.000Z</StatusDate><Source id="1869112" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusHistoric><Company id="29753">Infinity Pharmaceuticals Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="2054">Hematological neoplasm</Indication><StatusDate>2010-07-08T00:00:00.000Z</StatusDate><Source id="1115086" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1045250">Intellikine Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="2054">Hematological neoplasm</Indication><StatusDate>2009-05-18T00:00:00.000Z</StatusDate><Source id="1010606" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1045250">Intellikine Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="188">Inflammatory disease</Indication><StatusDate>2009-01-30T00:00:00.000Z</StatusDate><Source id="980315" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="29753">Infinity Pharmaceuticals Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="188">Inflammatory disease</Indication><StatusDate>2010-07-08T00:00:00.000Z</StatusDate><Source id="1115086" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1045514">Mundipharma International Corp Ltd</Company><Country id="GB">UK</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="2054">Hematological neoplasm</Indication><StatusDate>2010-07-08T00:00:00.000Z</StatusDate><Source id="1115086" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1045514">Mundipharma International Corp Ltd</Company><Country id="GB">UK</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="188">Inflammatory disease</Indication><StatusDate>2010-07-08T00:00:00.000Z</StatusDate><Source id="1115086" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="29753">Infinity Pharmaceuticals Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="36">Autoimmune disease</Indication><StatusDate>2010-08-04T00:00:00.000Z</StatusDate><Source id="1121385" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1045250">Intellikine Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="36">Autoimmune disease</Indication><StatusDate>2010-08-04T00:00:00.000Z</StatusDate><Source id="1121385" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1045514">Mundipharma International Corp Ltd</Company><Country id="GB">UK</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="188">Inflammatory disease</Indication><StatusDate>2011-10-31T00:00:00.000Z</StatusDate><Source id="1234966" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1045514">Mundipharma International Corp Ltd</Company><Country id="GB">UK</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="2054">Hematological neoplasm</Indication><StatusDate>2011-10-31T00:00:00.000Z</StatusDate><Source id="1234966" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="29753">Infinity Pharmaceuticals Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="291">Rheumatoid arthritis</Indication><StatusDate>2012-08-07T00:00:00.000Z</StatusDate><Source id="1313779" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="29753">Infinity Pharmaceuticals Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="291">Rheumatoid arthritis</Indication><StatusDate>2013-05-13T00:00:00.000Z</StatusDate><Source id="1419618" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="29753">Infinity Pharmaceuticals Inc</Company><Country id="X5">Europe</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="2054">Hematological neoplasm</Indication><StatusDate>2013-03-12T00:00:00.000Z</StatusDate><Source id="1394087" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="29753">Infinity Pharmaceuticals Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="319">Non-Hodgkin lymphoma</Indication><StatusDate>2013-05-31T00:00:00.000Z</StatusDate><Source id="1518351" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="29753">Infinity Pharmaceuticals Inc</Company><Country id="X5">Europe</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="319">Non-Hodgkin lymphoma</Indication><StatusDate>2015-02-02T00:00:00.000Z</StatusDate><Source id="1518351" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="29753">Infinity Pharmaceuticals Inc</Company><Country id="GB">UK</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="31">Asthma</Indication><StatusDate>2012-07-19T00:00:00.000Z</StatusDate><Source id="1312702" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1072507">AbbVie Inc</Company><Country id="JP">Japan</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="203">Lymphoma</Indication><StatusDate>2015-11-30T00:00:00.000Z</StatusDate><Source id="1747936" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1072507">AbbVie Inc</Company><Country id="JP">Japan</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="2054">Hematological neoplasm</Indication><StatusDate>2016-03-30T00:00:00.000Z</StatusDate><Source id="1747791" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="29753">Infinity Pharmaceuticals Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="2054">Hematological neoplasm</Indication><StatusDate>2011-10-31T00:00:00.000Z</StatusDate><Source id="1234966" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="29753">Infinity Pharmaceuticals Inc</Company><Country id="CA">Canada</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="1734">Chronic lymphocytic leukemia</Indication><StatusDate>2015-02-28T00:00:00.000Z</StatusDate><Source id="1683138" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="29753">Infinity Pharmaceuticals Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="311">T-cell lymphoma</Indication><StatusDate>2014-01-23T00:00:00.000Z</StatusDate><Source id="1518220" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="29753">Infinity Pharmaceuticals Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="188">Inflammatory disease</Indication><StatusDate>2011-10-31T00:00:00.000Z</StatusDate><Source id="1234966" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="29753">Infinity Pharmaceuticals Inc</Company><Country id="JP">Japan</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="203">Lymphoma</Indication><StatusDate>2015-11-30T00:00:00.000Z</StatusDate><Source id="1747936" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="29753">Infinity Pharmaceuticals Inc</Company><Country id="JP">Japan</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="2054">Hematological neoplasm</Indication><StatusDate>2016-06-28T00:00:00.000Z</StatusDate><Source id="1776420" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="29753">Infinity Pharmaceuticals Inc</Company><Country id="CA">Canada</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="319">Non-Hodgkin lymphoma</Indication><StatusDate>2015-02-02T00:00:00.000Z</StatusDate><Source id="1518351" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="29753">Infinity Pharmaceuticals Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="1734">Chronic lymphocytic leukemia</Indication><StatusDate>2013-11-30T00:00:00.000Z</StatusDate><Source id="1509881" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="29753">Infinity Pharmaceuticals Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="1745">Follicle center lymphoma</Indication><StatusDate>2014-09-08T00:00:00.000Z</StatusDate><Source id="1593369" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="29753">Infinity Pharmaceuticals Inc</Company><Country id="CA">Canada</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="1745">Follicle center lymphoma</Indication><StatusDate>2014-09-08T00:00:00.000Z</StatusDate><Source id="1593369" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="29753">Infinity Pharmaceuticals Inc</Company><Country id="NZ">New Zealand</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="1745">Follicle center lymphoma</Indication><StatusDate>2014-09-08T00:00:00.000Z</StatusDate><Source id="1593369" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="29753">Infinity Pharmaceuticals Inc</Company><Country id="X5">Europe</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="1745">Follicle center lymphoma</Indication><StatusDate>2014-09-08T00:00:00.000Z</StatusDate><Source id="1593369" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="29753">Infinity Pharmaceuticals Inc</Company><Country id="AU">Australia</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="1745">Follicle center lymphoma</Indication><StatusDate>2014-09-08T00:00:00.000Z</StatusDate><Source id="1593369" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="29753">Infinity Pharmaceuticals Inc</Company><Country id="X5">Europe</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="1734">Chronic lymphocytic leukemia</Indication><StatusDate>2015-01-28T00:00:00.000Z</StatusDate><Source id="1509881" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="29753">Infinity Pharmaceuticals Inc</Company><Country id="NZ">New Zealand</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="1734">Chronic lymphocytic leukemia</Indication><StatusDate>2015-01-28T00:00:00.000Z</StatusDate><Source id="1509881" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="29753">Infinity Pharmaceuticals Inc</Company><Country id="AU">Australia</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="1734">Chronic lymphocytic leukemia</Indication><StatusDate>2015-01-28T00:00:00.000Z</StatusDate><Source id="1509881" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="29753">Infinity Pharmaceuticals Inc</Company><Country id="GB">UK</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="1734">Chronic lymphocytic leukemia</Indication><StatusDate>2013-12-06T00:00:00.000Z</StatusDate><Source id="1509881" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1072507">AbbVie Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="651">Cancer</Indication><StatusDate>2014-09-03T00:00:00.000Z</StatusDate><Source id="1589923" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1058061">Verastem Oncology</Company><Country id="US">US</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="1734">Chronic lymphocytic leukemia</Indication><StatusDate>2016-11-02T00:00:00.000Z</StatusDate><Source id="1869112" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1058061">Verastem Oncology</Company><Country id="US">US</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="1745">Follicle center lymphoma</Indication><StatusDate>2016-11-02T00:00:00.000Z</StatusDate><Source id="1869112" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1058061">Verastem Oncology</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="1753">Peripheral T-cell lymphoma</Indication><StatusDate>2017-09-06T00:00:00.000Z</StatusDate><Source id="1959382" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1058061">Verastem Oncology</Company><Country id="JP">Japan</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="1753">Peripheral T-cell lymphoma</Indication><StatusDate>2017-09-06T00:00:00.000Z</StatusDate><Source id="1959382" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1058061">Verastem Oncology</Company><Country id="JP">Japan</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="203">Lymphoma</Indication><StatusDate>2016-11-02T00:00:00.000Z</StatusDate><Source id="1869112" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1058061">Verastem Oncology</Company><Country id="JP">Japan</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="1753">Peripheral T-cell lymphoma</Indication><StatusDate>2018-05-03T00:00:00.000Z</StatusDate><Source id="2030492" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1058061">Verastem Oncology</Company><Country id="JP">Japan</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="2054">Hematological neoplasm</Indication><StatusDate>2016-11-02T00:00:00.000Z</StatusDate><Source id="1869112" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1058061">Verastem Oncology</Company><Country id="US">US</Country><DevelopmentStatus id="PR" sortOrder="13">Pre-registration</DevelopmentStatus><Indication id="1734">Chronic lymphocytic leukemia</Indication><StatusDate>2018-02-07T00:00:00.000Z</StatusDate><Source id="2003428" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1058061">Verastem Oncology</Company><Country id="US">US</Country><DevelopmentStatus id="PR" sortOrder="13">Pre-registration</DevelopmentStatus><Indication id="1745">Follicle center lymphoma</Indication><StatusDate>2018-02-07T00:00:00.000Z</StatusDate><Source id="2003428" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1058061">Verastem Oncology</Company><Country id="US">US</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="1734">Chronic lymphocytic leukemia</Indication><StatusDate>2018-09-24T00:00:00.000Z</StatusDate><Source id="2075937" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1058061">Verastem Oncology</Company><Country id="US">US</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="1745">Follicle center lymphoma</Indication><StatusDate>2018-09-24T00:00:00.000Z</StatusDate><Source id="2075937" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1058061">Verastem Oncology</Company><Country id="CA">Canada</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="1745">Follicle center lymphoma</Indication><StatusDate>2016-11-02T00:00:00.000Z</StatusDate><Source id="1869112" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1058061">Verastem Oncology</Company><Country id="NZ">New Zealand</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="1745">Follicle center lymphoma</Indication><StatusDate>2016-11-02T00:00:00.000Z</StatusDate><Source id="1869112" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1058061">Verastem Oncology</Company><Country id="X5">Europe</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="1745">Follicle center lymphoma</Indication><StatusDate>2016-11-02T00:00:00.000Z</StatusDate><Source id="1869112" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1058061">Verastem Oncology</Company><Country id="AU">Australia</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="1745">Follicle center lymphoma</Indication><StatusDate>2016-11-02T00:00:00.000Z</StatusDate><Source id="1869112" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="29753">Infinity Pharmaceuticals Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="319">Non-Hodgkin lymphoma</Indication><StatusDate>2015-12-31T00:00:00.000Z</StatusDate><Source id="1700592" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1045250">Intellikine Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="711">Respiratory disease</Indication><StatusDate>2009-05-18T00:00:00.000Z</StatusDate><Source id="1010606" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="29753">Infinity Pharmaceuticals Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="711">Respiratory disease</Indication><StatusDate>2010-07-08T00:00:00.000Z</StatusDate><Source id="1115086" type="PR"/></DevelopmentStatusHistoric></IDdbDevelopmentStatus><RegulatoryDesignationStatus><Row><RegulatoryDesignation id="5">Accelerated Approval</RegulatoryDesignation><OwnerCompany id="29753">Infinity Pharmaceuticals Inc</OwnerCompany><Country id="US">US</Country><Indication id="1745">Follicle center lymphoma</Indication><AwardedIndication>Treatment of relapsed or refractory follicular lymphoma in patients who have received at least two prior therapies</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="1">Granted</DesignationApplicationStatus><MileStoneDate>2018-09-24T00:00:00.000Z</MileStoneDate><Source id="2075937" type="PR"/></Row><Row><RegulatoryDesignation id="5">Accelerated Approval</RegulatoryDesignation><OwnerCompany id="29753">Infinity Pharmaceuticals Inc</OwnerCompany><Country id="US">US</Country><Indication id="1745">Follicle center lymphoma</Indication><AwardedIndication>Treatment of relapsed or refractory follicular lymphoma</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="3">Filed</DesignationApplicationStatus><MileStoneDate>2018-02-07T00:00:00.000Z</MileStoneDate><Source id="2003428" type="PR"/></Row><Row><RegulatoryDesignation id="5">Accelerated Approval</RegulatoryDesignation><OwnerCompany id="29753">Infinity Pharmaceuticals Inc</OwnerCompany><Country id="US">US</Country><Indication id="1745">Follicle center lymphoma</Indication><AwardedIndication>Treatment of patients with relapsed or refractory follicular lymphoma (FL)</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="4">Planned</DesignationApplicationStatus><MileStoneDate>2016-06-28T00:00:00.000Z</MileStoneDate><Source id="1776420" type="PR"/></Row><Row><RegulatoryDesignation id="2">Fast Track</RegulatoryDesignation><OwnerCompany id="29753">Infinity Pharmaceuticals Inc</OwnerCompany><Country id="US">US</Country><Indication id="1753">Peripheral T-cell lymphoma</Indication><AwardedIndication>Treatment of peripheral T-cell lymphoma patients who have received at least one prior therapy</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="1">Granted</DesignationApplicationStatus><MileStoneDate>2017-09-06T00:00:00.000Z</MileStoneDate><Source id="1959382" type="PR"/></Row><Row><RegulatoryDesignation id="2">Fast Track</RegulatoryDesignation><OwnerCompany id="29753">Infinity Pharmaceuticals Inc</OwnerCompany><Country id="US">US</Country><Indication id="1745">Follicle center lymphoma</Indication><AwardedIndication>The treatment of follicular lymphoma who have received at least two prior therapies</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="1">Granted</DesignationApplicationStatus><MileStoneDate>2017-03-23T00:00:00.000Z</MileStoneDate><Source id="1911968" type="CORPORATE"/></Row><Row><RegulatoryDesignation id="2">Fast Track</RegulatoryDesignation><OwnerCompany id="29753">Infinity Pharmaceuticals Inc</OwnerCompany><Country id="US">US</Country><Indication id="1734">Chronic lymphocytic leukemia</Indication><AwardedIndication>The treatment of patients with chronic lymphocytic leukemia who have received at least one prior therapy</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="1">Granted</DesignationApplicationStatus><MileStoneDate>2015-08-06T00:00:00.000Z</MileStoneDate><Source id="1684309" type="PR"/></Row><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="29753">Infinity Pharmaceuticals Inc</OwnerCompany><Country id="US">US</Country><Indication id="1745">Follicle center lymphoma</Indication><AwardedIndication>Treatment of follicular lymphoma</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="1">Granted</DesignationApplicationStatus><MileStoneDate>2013-08-01T00:00:00.000Z</MileStoneDate><Source id="1462442" type="CORPORATE"/></Row><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="29753">Infinity Pharmaceuticals Inc</OwnerCompany><Country id="EU">EU</Country><Indication id="1745">Follicle center lymphoma</Indication><AwardedIndication>Treatment of follicular lymphoma</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="1">Granted</DesignationApplicationStatus><MileStoneDate>2013-07-17T00:00:00.000Z</MileStoneDate><Source id="1475233" type="PR"/></Row><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="29753">Infinity Pharmaceuticals Inc</OwnerCompany><Country id="EU">EU</Country><Indication id="1745">Follicle center lymphoma</Indication><AwardedIndication>Treatment of follicular lymphoma</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="2">Positive Opinion</DesignationApplicationStatus><MileStoneDate>2013-06-13T00:00:00.000Z</MileStoneDate><Source id="1442730" type="PR"/></Row><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="29753">Infinity Pharmaceuticals Inc</OwnerCompany><Country id="EU">EU</Country><Indication id="1734">Chronic lymphocytic leukemia</Indication><AwardedIndication>Treatment of chronic lymphocytic leukaemia / small lymphocytic lymphoma</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="1">Granted</DesignationApplicationStatus><MileStoneDate>2013-04-26T00:00:00.000Z</MileStoneDate><Source id="1429040" type="PR"/></Row><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="29753">Infinity Pharmaceuticals Inc</OwnerCompany><Country id="US">US</Country><Indication id="1734">Chronic lymphocytic leukemia</Indication><AwardedIndication>Treatment of chronic lymphocytic leukemia and small lymphocytic lymphoma</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="1">Granted</DesignationApplicationStatus><MileStoneDate>2013-04-15T00:00:00.000Z</MileStoneDate><Source id="1408141" type="CORPORATE"/></Row><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="29753">Infinity Pharmaceuticals Inc</OwnerCompany><Country id="EU">EU</Country><Indication id="1734">Chronic lymphocytic leukemia</Indication><AwardedIndication>Treatment of chronic lymphocytic leukaemia / small lymphocytic lymphoma</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="2">Positive Opinion</DesignationApplicationStatus><MileStoneDate>2013-03-13T00:00:00.000Z</MileStoneDate><Source id="1394087" type="PR"/></Row><Row><RegulatoryDesignation id="11">Priority Review</RegulatoryDesignation><OwnerCompany id="29753">Infinity Pharmaceuticals Inc</OwnerCompany><Country id="US">US</Country><Indication id="1734">Chronic lymphocytic leukemia</Indication><AwardedIndication>Treatment of relapsed or refractory CLL/SLL</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="1">Granted</DesignationApplicationStatus><MileStoneDate>2018-04-09T00:00:00.000Z</MileStoneDate><Source id="2020301" type="PR"/></Row></RegulatoryDesignationStatus><Targets><Target id="PTGT-02712"><Name>Phosphoinositide-3 kinase delta</Name><SwissprotNumbers><Swissprot>O00329</Swissprot><Swissprot>O35904</Swissprot></SwissprotNumbers></Target><Target id="PTGT-02713"><Name>Phosphoinositide-3 kinase gamma</Name><SwissprotNumbers><Swissprot>O02697</Swissprot><Swissprot>P48736</Swissprot><Swissprot>Q9JHG7</Swissprot></SwissprotNumbers></Target></Targets><ReasonsForUpdate><ReasonForUpdate><Reason>Reference Added</Reason><Description>1 reference added [&lt;ulink url="utility.reference?i_reference_id=2166893" linkType="reference" linkID="2166893"&gt;2166893&lt;/ulink&gt;]							</Description></ReasonForUpdate></ReasonsForUpdate><CountsByCompanies><Company><Company id="1022451">China Pharma Holdings Inc</Company><CountAsPrincipalActive>1</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>1</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="1034675">Catalent Inc</Company><CountAsPrincipalActive>0</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>0</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="1038741">The Leukemia &amp; Lymphoma Society</Company><CountAsPrincipalActive>1</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>1</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="1043620">Healthcare Royalty Partners</Company><CountAsPrincipalActive>1</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>1</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="1045514">Mundipharma International Corp Ltd</Company><CountAsPrincipalActive>0</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>0</CountAsPartnerActive><CountAsPartnerInactive>1</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="1058061">Verastem Oncology</Company><CountAsPrincipalActive>4</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>4</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>8</CountTotal></Company><Company><Company id="1063427">Pharm-Olam International</Company><CountAsPrincipalActive>0</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>0</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="1072507">AbbVie Inc</Company><CountAsPrincipalActive>0</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>0</CountAsPartnerActive><CountAsPartnerInactive>1</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="1131794">US Bioservices</Company><CountAsPrincipalActive>0</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>0</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="1145559">Hercules Capital Inc</Company><CountAsPrincipalActive>1</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>1</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="19446">Roche Holding AG</Company><CountAsPrincipalActive>0</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>0</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="20300">Takeda Pharmaceutical Co Ltd</Company><CountAsPrincipalActive>0</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>0</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="20961">Yakult Honsha Co Ltd</Company><CountAsPrincipalActive>1</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>1</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="22122">Memorial Sloan-Kettering Cancer Center</Company><CountAsPrincipalActive>0</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>0</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="29753">Infinity Pharmaceuticals Inc</Company><CountAsPrincipalActive>3</CountAsPrincipalActive><CountAsPrincipalInactive>2</CountAsPrincipalInactive><CountAsPartnerActive>3</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>7</CountTotal></Company></CountsByCompanies><CountsByTypes><Type><Type sortOrder="13">Drug - Funding</Type><CountActive>1</CountActive><CountInactive>0</CountInactive><CountTotal>1</CountTotal></Type><Type><Type sortOrder="2">Drug - Screening/Evaluation</Type><CountActive>1</CountActive><CountInactive>0</CountInactive><CountTotal>1</CountTotal></Type><Type><Type sortOrder="4">Drug - Development/Commercialization License</Type><CountActive>5</CountActive><CountInactive>2</CountInactive><CountTotal>7</CountTotal></Type><Type><Type sortOrder="5">Drug - Commercialization License</Type><CountActive>1</CountActive><CountInactive>0</CountInactive><CountTotal>1</CountTotal></Type><Type><Type sortOrder="6">Drug - Manufacturing/Supply</Type><CountActive>2</CountActive><CountInactive>0</CountInactive><CountTotal>2</CountTotal></Type><Type><Type sortOrder="7">Drug - Development Services</Type><CountActive>2</CountActive><CountInactive>0</CountInactive><CountTotal>2</CountTotal></Type></CountsByTypes><StructureSmiles><Smiles>C[C@@H](c1cc2cccc(c2c(=O)n1c3ccccc3)Cl)Nc4c5c([nH]cn5)ncn4</Smiles><Smiles>C[C@@H](c1cc2cccc(c2c(=O)n1c3ccccc3)Cl)Nc4c5c([nH]cn5)ncn4.O</Smiles></StructureSmiles><Deals><Deal id="118077" title="Infinity and Mundipharma to codevelop Infinity's early R&amp;D programs outside of US  "/><Deal id="131150" title="Infinity to develop Intellikine's PI3K delta/gamma inhibitors for inflammatory disease and cancers worldwide              "/><Deal id="150702" title="Roche and Infinity agreed to cosupply Gazyva and duvelisib for haematologic malignancies    "/><Deal id="150706" title="Infinity Pharmaceuticals and AbbVie to develop duvelisib for cancer worldwide with Abbvie commercializing outside the US         "/><Deal id="158900" title="Pharm-Olam to provide CRO services for Infinity's phase II study against relapsed/refractory follicular lymphoma    "/><Deal id="197734" title="Verastem to develop and commercialise Infinity's duvelisib for hematologic malignancies worldwide  "/><Deal id="237530" title="Hercules Capital to award Verastem loan to develop duvelisib"/><Deal id="247346" title="Yakult Honsha to develop and commercialize Verastem's duvelisib for all oncology indications in Japan "/><Deal id="250001" title="CSPC Pharmaceuticals to develop and commercialize Verastem's duvelisib for oncology in China, Hong Kong, Macau and Taiwan"/><Deal id="250072" title="US Bioservices to distribute Verastem Oncology's Copiktra capsules for CLL/SLL in the US"/><Deal id="250570" title="Catalent to provide development and analytical and manufacturing services to Verastem's Copiktra for CLL/SLL   "/><Deal id="251068" title="LLS and Verastem to develop duvelisib for the treatment of PTCL   "/><Deal id="251088" title="Memorial to evaluate Verastem's duvelisib in combination with romidepsin for relapsed or refractory PTCL   "/><Deal id="253962" title="HCR to purchase Infinity's royalty stream for Copiktra        "/></Deals><PatentFamilies><PatentFamily id="2659331" number="WO-2014004470" title="Treatment of lupus, fibrotic conditions, and inflammatory myopathies and other disorders using pi3 kinase inhibitors"/><PatentFamily id="2726913" number="WO-2014071105" title="Treatment of rheumatoid arthritis and asthma using PI3 kinase inhibitors"/><PatentFamily id="2726921" number="WO-2014071109" title="Treatment of cancers using PI3 kinase isoform modulators"/><PatentFamily id="2734026" number="WO-2014072937" title="Pharmaceutical compositions containing a PDE4 inhibitor and a PI3 delta or dual PI3 delta-gamma kinase inhibitor"/><PatentFamily id="2915593" number="WO-2015054099" title="Combinations of histone deacetylase inhibitors and either her2 inhibitors or pi3k inhibitors"/><PatentFamily id="3055991" number="WO-2015160975" title="Combination therapies"/><PatentFamily id="3234182" number="WO-2016127844" title="Î crystal form of IPI-145 and preparation method thereof"/><PatentFamily id="3480173" number="EP-03150609" title="Process for preparing certain chemical entities"/><PatentFamily id="3593610" number="WO-2009088986" title="Certain chemical entities, compositions and methods"/><PatentFamily id="3668834" number="WO-2017087207" title="Deuterated compounds for treating hematologic malignant, inflammatory and autoimmune diseases"/><PatentFamily id="3895263" number="WO-2017223422" title="Combination therapies"/><PatentFamily id="4266944" number="CN-108743947" title="A pharmaceutical composition for treating b-cell lymphoma"/><PatentFamily id="676856" number="WO-2012097000" title="Processes for preparing isoquinolinones and solid forms of isoquinolinones"/></PatentFamilies><PatentFamilyCountsByTypes><PatentFamilyCountsByType><Type sortorder="12">Product</Type><Count>2</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="13">Product (derivative)</Type><Count>3</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="3">Component of Combination</Type><Count>5</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="9">New use</Type><Count>6</Count></PatentFamilyCountsByType></PatentFamilyCountsByTypes><PatentFamilyCountsByCompanies><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Rhizen Pharmaceuticals SA" id="1052344"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Fudan University Shanghai Cancer Center" id="1071075"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="AbbVie Inc" id="1072507"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Crystal Pharmatech Co Ltd" id="1077753"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Neuform Pharmaceuticals Inc" id="1147161"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Celgene Corp" id="15331"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="CJ Corp" id="15473"/><CountAsOwner>2</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>2</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Takeda Pharmaceutical Co Ltd" id="20300"/><CountAsOwner>3</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>3</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Individual" id="21144"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Infinity Pharmaceuticals Inc" id="29753"/><CountAsOwner>8</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>8</CountTotal></PatentFamilyCountsByCompany></PatentFamilyCountsByCompanies><hasSWOTs>Y</hasSWOTs></drugRecordOutput>